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          Despite the tremendous potential of short interfering RNA (siRNA) as a novel 
biopharmaceutical, its therapeutic utility has not been maximized mainly due to lack of 
proper in vivo delivery vehicle, off-target effects and several off-pathway protein 
interactions instigating immunostimulation. Judicious chemical modification of different 
parts of the siRNA was foreseen as a potential solution to the off-target gene silencing 
and the off-pathway protein binding.  
          In this study, 8-alkoxyadenosines were explored as a nucleobase modification in 
the context of the siRNA-based RNA interference (RNAi). These nucleosides are unusual 
in that they have the potential to exist as an equilibrium mixture of the syn and anti 
conformers. When placed opposite to U in the complementary strand, 8-
alkoxyadenosines can exist in normal anti conformation and form canonical Watson-
Crick hydrogen bonding; interestingly, with G as the base-pairing partner, these unusual 
nucleosides can potentially flip into the syn conformation and form unorthodox 
Hoogsteen base-pairing.  
          8-Alkoxyadenosine phosphoramidites were synthesized and incorporated into the 
guide strand of caspase 2 siRNA at four different positions - two in the seed region, one 
at the cleavage junction and another nearer to the 3´-end of the guide strands. Thermal 
stabilities of the corresponding siRNA duplexes showed that U is still preferred over G as 
the base-pairing partner in the complementary strand. When compared to the unmodified 	  
	   iv	  
positive control siRNAs, singly modified siRNAs have knocked down caspase 2 insert 
mRNA (generated from a recombinant plasmid) efficiently and with little or no loss of 
efficacy. Doubly modified siRNAs were found to be less effective and lose their efficacy 
at low nanomolar concentrations. Persistent placement of steric blockade in the minor 
groove affected the RNAi efficacy significantly; this observation supports the hypothesis 
and indicates the necessity of ‘switching’ the bulky alkyloxy groups in the major groove, 
when modified siRNAs interact with the RISC assembly.   
          SiRNAs modified at positions 6 and 10 of the guide strand were found to be 
effective against preventing interaction with the RNA-dependent protein kinase (PKR). 
In summary, 8-alkoxyadenosine-containing siRNAs prevented undesired off-pathway 
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RNA interference and short interfering RNA  
 
          RNA interference (RNAi) has become a crucial tool to interrogate and analyze 
gene function since the discovery of double stranded RNA (dsRNA)-mediated RNAi in 
C. elegans in 1998 (1). Theoretically, any mRNA in vitro or in vivo can selectively be 
knocked down by short RNA oligomers containing 19-23 nucleotides called short 
interfering RNAs (siRNAs). In 2001, Elbashir et al. showed that RNAi was effective in 
mammalian cells, and the therapeutic potential of siRNA was quickly understood (2). 
This finding triggered a plethora of research on utilization of siRNA as therapeutics (3-6).  
          SiRNA-mediated gene silencing is highly selective provided siRNAs are rationally 
chosen. Thermodynamic stability of the duplex is an important determining factor. The 
duplex should be less stable towards the 5´-end of the guide strand compared to the 3´-
end. Nucleotides 2-8 from the 5´-end of the guide strand, also called the seed region of an 
siRNA (Figure 1.1), play crucial roles in mRNA knockdown efficiency and specificity. 
Nucleotides 10 and 11 are the cleavage site nucleotides; the mRNA cleavage occurs 
between these two positions. Generally, there should be perfect base pairing in the seed 
region and at the cleavage site for optimal efficacy; sometimes, mismatches (7, 8) are 
tolerated at the expense of RNAi efficacy.  
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          SiRNAs can be generated in the cell from long dsRNAs (by Dicer) or can be 
chemically synthesized and delivered inside cells to mediate specific mRNA cleavage 
(Figure 1.2). Upon entry into the cellular environment, siRNA is phosphorylated at the 
5´-end of the strands and loaded into the RNA-induced silencing complex (RISC). In the 
RISC, enzyme helicase unwind the siRNA and the active siRNP complex is generated 
where the guide strand mediates the cleavage of complementary mRNA. 
 
RNAi: Proof-of-principle in animal models 
          Local RNAi in animal models. To date, most of the siRNAs have been 
successfully applied through local administration. Specific silencing of target genes has 
been achieved in animal models of human diseases using appropriate siRNA or shRNA 
(short hairpin RNA). The RNAi concept has been validated in multiple organs such as, 
lung (10, 11), brain (12-20), colon (21, 22), eye (23-25), and vagina(26) and diseases 
including viral infection (10, 11, 27, 28), nervous diseases (12-16, 29, 30), cancers (22, 
31-36), irritable bowel syndrome(21), etc.(37) (Figure 1.3).  
          Highly promising results have been obtained in rodent (mouse) and primate 
(monkey) models of severe acute respiratory syndrome (SARS) (11), RSV (respiratory 
syncitical virus) and influenza. The cationic polymer-based transfection reagent TransIT 
TKO has successfully led to intranasal delivery of siRNAs against RSV and para-
influenza virus into pulmonary tissues and reduced the infection by more than 99% (10). 
Lethal Ebola virus infection was successfully countered by administration of SNALP-
formulated siRNAs in guinea pigs (28). 
          RNAi proof-of-concept studies have been demonstrated in numerous ocular 
diseases, in animal models, through local intravitreal delivery of specific siRNA. SiRNAs 


















































Figure 1.3. Organs and diseases where siRNA-based RNAi has been demonstrated. 
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targeting vascular endothelial growth factor (VEGF) receptor-1 and transforming growth 
factor (TGF)-β receptor type II were effective in shrinking ocular neovascularization and 
preventing choroidal neovascularization respectively in two separate mouse models (23, 
24). For local siRNA delivery in the eye, saline and lipid formulations were proven 
effective. Mucosal membranes in colon, nose and genitals are accessible to various 
siRNA formulations, e.g., lipofectamine formulated siRNAs targeting TNF-α in IBS has 
been shown to reduce TNF-α abundance, as well as reduce inflammation of the colon 
(21). 
          ShRNA- or siRNA-based RNAi was shown to be effective in vivo in numerous 
nervous disease models (12-16, 29, 30). RNAi has brought about marked reduction in 
disease phenotypes and neuropathology (16) in the xenograft models of Alzheimer’s 
disease (16), Huntington’s disease (13), amyotrophic lateral sclerosis (ALS) (14, 15), 
chronic neuropathic pain (38), cerebellar ataxia (12), encephalitis (30), etc. In these 
studies on specific neurons, even 10-20% reduction of the target gene expression has 
been reported to normalize disease symptoms significantly (16).  
          The RNAi concept has also been validated in different mouse xenograft models of 
human cancers through appropriate delivery vehicles (37), such as lipids (31, 39, 40), 
polymers (41), cholesterol-oligoarginine (22), protamine-Fab fusion protein (42), and 
aptamers (43). Aptamer-based chimeric siRNAs promise to be the most simplified and 
selective approach, provided an aptamer is available for a tumor specific receptor. 
Aptamer-siRNA conjugates have successfully prevented tumor growth in xenograft 
models of prostate cancer (34). 
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           Systemic RNAi in animal models. In systemic administration of siRNA, RNAi 
efficacy is dependent on the choice of delivery vehicles and chemical modifications. 
Systemic RNAi (44, 45) has been demonstrated in mouse models of several diseases such 
as hypercholesterolemia (46), rheumatoid arthritis, viral infections (hepatitis B virus (27) 
, influenza virus, Ebola virus (28)) and in tumor xenografts. Cholesterol-conjugated and 
SNALP (stable nucleic acid lipid particle)-formulated siRNAs have been shown to 
silence apolipoprotein apoB in nonhuman primates (47).  
            A spectrum of delivery vehicles has successfully delivered anticancer siRNAs 
into various malignant tumors. Cationic cardiolipin liposome formulated siRNAs, when 
delivered intravenously, prevented tumor growth in xenograft model of prostate cancer 
(48). Systemic administration of PEGylated PEI-Arg-Gly-Asp nanoparticle formulated 
siRNAs targeting VEGF R-2 (vascular endothelial growth factor receptor-2) has 
prevented tumor angiogenesis and growth (49). Cholesterol-conjugated siRNAs targeting 
VEGF receptor inhibited tumor growth in colon adenocarcinoma (22). Intravenous 
delivery of atelo-collagen-siRNA complexes have pronounced effects on bone tumors 
(35) and subcutaneous tumor xenografts (50). Ligand-directed systemic delivery of 
siRNA is gradually gaining importance; siRNA complexed with transferrin-anchored 
polymeric nanoparticles has shrunk metastatic Ewing sarcoma (36).  
 
SiRNA clinical trials 
          In spite of the challenges of finding appropriate delivery vehicles for siRNA, at 
least eleven siRNAs are currently in clinical trials (Table 1.1). Validation of the siRNA-
based RNAi in xenograft models of human diseases has encouraged clinical trials of 
siRNAs in the treatment of several diseases (3, 51, 52). Prior success with antisense oligo 
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nucleotides, led to initial clinical trials of siRNAs targeting ocular diseases such as AMD 
and diabetic macular edema (DME). In both the cases VEGF pathway was targeted 
locally with intraocular injection of siRNA. After initial clinical trials both were 
withdrawn from the market due to safety reasons and availability of alternative 
therapeutics (53). Still, the eye is an attractive target for RNAi validation (54, 55). 
SiRNA (PF-04523655) targeting hypoxia-responsive gene RTP801 to treat AMD and 
DME is already in advanced clinical trial (phase II) (55); visual acuity is restored in 90% 
of the patients in a preliminary study. Two other drugs for the treatment of glaucoma are 
currently under phase I clinical trial (6). 
          Due to high efficacy and specificity of siRNAs against RSV in mice models, 
Alnylam has designed ALN-RSV01 siRNA, which is currently in phase II clinical trial 
(56). Two siRNAs, for acute renal failure and asthma, are under phase II clinical trial at 
the moment (6). There has been significant advancement in the development of siRNAs 
targeting cancer. Several targets for siRNA therapeutics (under phase I clinical trial) in 
this category are ribonucleotide reductase (RRM2) for solid tumors, PKN3 for tumor 
vasculature in solid tumors, VEGF and KSP for liver cancer etc. Tekmira is developing 
lipid nanoparticle-formulated siRNAs targeting ApoB for hypercholesterolemia (6). All 
of them are being developed for systemic administration. Transderm is developing 
siRNAs against pachyonychia congenita, a keratin 6a abnormality; they have successfully 




          SiRNA delivery techniques have improved significantly over the last few years 
(Figure 1.4) (59). Polymeric or liposomal formulations reduced the dose requirement (per 
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day) of naked siRNA in efficacious RNAi; compared to 0.4 mg of siRNA formulated in 
PBS, only 5-40 µg is required if formulated in appropriate polymeric or liposomal 
delivery vehicles. Reduction in dosage also helps reduce undesired off-target effects and 
immunostimulation. Also in ocular clinical trials, it was found that only cholesterol-
conjugated siRNAs can enter the RNAi pathway and naked siRNAs merely interact with 
the innate immune system (60). These observations clearly suggest that appropriate 
delivery vehicles are essential for therapeutic efficacy of siRNA.  
          Polymeric nanocarriers are gradually gaining importance as siRNA delivery 
vehicles (41, 61-64). PEG-based and pH sensitive cationic copolymers (65), lactose-
conjugated pH-sensitive PEG (66) and chitosan-polyethylene oxide copolymer (67) have 
been shown to enhance intracellular gene silencing. Acid-lability and bioreduciblity of 
polymer backbones have been judiciously used for the controlled release of siRNA in 
desired targets (62, 66, 68). Recently, phosphonium ion-based cationic polymers were 
employed as a nontoxic alternative to the polyammonium carriers (69). Several 
macroscopic biomaterial scaffolds, such as PEG, alginate, photoalginate, collagen etc, 
have been reported for localized, targeted and sustained delivery of siRNA (63, 70). 
Proton sponge-anchored quantum dots have been used both to deliver siRNA to 
appropriate target and image the entire delivery and trafficking process inside cell (71, 
72).  
          Lipid-based delivery vehicles are also being successfully used for in vivo RNAi 
studies (Table 1.2) (39, 40, 73). SiRNAs-conjugated to lipid-like molecules have 
successfully delivered siRNAs in cultured cells and in vivo. These covalently conjugated 
lipidoids are promising for both local and systemic delivery of siRNA (74). 
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Table 1.2. In vivo delivery strategies for therapeutic siRNAs. (reproduced with 
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Cholesterol-conjugated siRNAs have shown to improve RNAi efficacy significantly both 
in cultured cells and in vivo (46, 76, 77). SiRNA conjugated to a single wall carbon 
nanotube efficiently delivered siRNA in cultured HeLa cells and lead to potent silencing 
of the lamin A/C gene (78).  
          To enhance the therapeutic potential of siRNA and reduce toxicity, targeted 
delivery is desired and required. Targeted delivery of siRNAs has been accomplished by 
anchoring an appropriate ligand (recognizable and taken up by a particular type of cell) to 
the delivery vehicle. Transferrin-anchored polycationic nanoparticles can selectively 
deliver siRNA into targeted cells by virtue of recognition of transferrin by specific 
receptors on the target cell surface (79). Folic acid (80, 81) or a specific carbohydrate,(66, 
82) when anchored to PEG oligomers, can direct the delivery of siRNAs to selective 
target or diseased cells, because many cells overexpress folate or carbohydrate receptors 
under abnormal conditions. PEG-decorated liposomes (SNALPs) can selectively deliver 
siRNAs in the livers of non-human primates; in one case the RNAi efficacy is >90% and 
one dose lasts for 11 days, indicating prolonged half-life of the siRNA in that formulation 
(47).  
           Conjugation of cell-penetrating peptides with siRNAs has also helped reduce 
dosage and improve RNAi efficacy (83). SiRNAs, when conjugated to liposomes, 
antibodies or neuropeptides can overcome the blood-brain barrier and can be delivered 
into the brain (3, 84). Antibody (targeting HIV 1 envelope protein gp160)-conjugated 
protamines can bind siRNAs (targeting HIV gene gag) electrostatically, and deliver 
siRNAs inside an HIV-infected murine model (42). Aptamers are gradually gaining 
popularity as delivery vehicles for the siRNA (85, 86). Aptamers are in vitro-evolved 
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synthetically prepared nucleic acid oligomers that can bind selectively and tightly to 
specific ligands; therefore aptamers can help the intracellular delivery of other 
biomolecules through selective aptamers-ligand interactions, provided an aptamer is 
available for the specific ligand (receptor or a part of the receptor) on the cell-surface. 
Prostate-specific membrane antigen-binding aptamers when conjugated to siRNAs 
targeting pro-survival genes in prostate cancer cells have been found to deliver the RNAi 
agent efficiently inside cells (43, 87). 
 
SiRNA therapeutics – pros and cons 
          SiRNA enjoys certain distinctive advantages over small molecule and protein 
based drugs. Small molecules have the limitation of being useful to “druggable” targets 
and the application of protein-based therapeutics is restricted to extracellular targets only; 
contrarily, RNAi can be extended to any biological target, including so called “non-
druggable” targets. Like protein-based antibodies and unlike small molecules, siRNAs 
are very selective and potent. It is much easier to synthesize short RNA oligomers than 
synthesizing complex organic molecules of biological significance; siRNA lead 
optimization is also much faster compared to protein-based drugs. 
          In spite of all these advantages of siRNA over other therapeutics, the therapeutic 
potential of RNAi has not been fully exercised yet because of numerous problems 
associated, such as ineffective delivery, poor nuclease-stability and numerous undesired 
side effects. SiRNA molecules, unlike small molecules, have high negative charges in its 
backbone and hence cannot cross the cellular membrane without the aid of delivery 
vehicles. Either covalent conjugation with other groups or noncovalent assembly with 
other materials is essential for their intracellular delivery.  
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          Optimal thermal and nuclease stability is essential for the therapeutic efficiency of 
siRNAs. Double stranded RNAs are much more stable compared to the single stranded 
ones toward nucleases. Generally, siRNAs are designed so that the duplex is of 
intermediate thermal stability – if the stability is very high, the RNAi machinery might 
not be able to unwind the siRNA for selective mRNA knock down; again, if the duplex is 
unstable (i.e., the melting temperature is low), then the siRNA will be an ineffective one 
since higher percentage of siRNA will exist as single strands which will be rapidly 
degraded by serum ribonucleases. Several chemical modifications have been reported to 
improve the thermal and the nuclease stability of siRNAs and these modifications do not 
affect the RNAi efficacy too much.    
          Native siRNAs can have off-target effects and instigate immunostimulation; these 
lower the specificity of siRNA action and induce toxicity inside cells. Several types of 
off-target effects can arise with siRNA-based therapeutics. Perfect complementarity of 
various regions of multiple mRNAs with the ‘seed’ region of an siRNA is a possible 
source of undesired side effect. To overcome this problem, several siRNAs are chosen as 
potential candidates and the one with optimal silencing efficacy and minimal ability to 
instigate non-target gene repression is chosen as the most promising compound. Judicious 
chemical modifications are another alternative to achieve RNAi selectivity and avoid 
undesired repression of non-target gene expression.  
 
Chemical modifications of the siRNA 
          Analogous to the well-known antisense technology, chemical modifications of 
siRNA have promise in improving siRNA properties such as enhanced duplex stability, 
improved nuclease resistance, higher potency, higher specificity etc. Also, chemically 
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modified siRNAs have facilitated cellular uptake, enhanced half-life, improved 
biodistribution and better pharmacokinetics. Naked siRNAs are rapidly degraded and 
excreted through the urinary system. Therefore, suitable chemical modifications are 
required for the translation of siRNA into potent therapeutics; in fact a large proportion of 
the siRNAs currently in clinical trial are chemically modified (6). SiRNA modifications 
can be classified into several categories: ribose modifications, backbone modifications, 
base modifications and terminal modifications including conjugation to other biologically 
significant molecules. 
           Ribose modifications. Ribose modifications are the most explored chemical 
modifications of the siRNA; from subtle to extensive modification of the sugar moiety 
have been reported (Figure 1.5). Modifications of the ribose moiety (88-105) have 
improved siRNA stability (88, 96), ribonuclease resistance (88, 90, 93, 95, 99), potency 
(90, 95, 104), and specificity (88, 106). 2´-OH of the sugar moiety has been modified 
more frequently than any other positions. 2´-deoxy (94), 2´-F (90) or 2´-N3 (97) 
substitutions did not significantly affect RNAi efficacy. 2´-Deoxy modifications lower 
the Tm of the siRNAs slightly, but are tolerated at the terminal of each strands and at the 
overhangs; however substitution of one of the strands with 2´-deoxy nucleosides (i.e., 
RNA:DNA hybrid) completely abolishes the RNAi activity (94, 107).  2´-NH2 
substitutions maintains RNAi activity, but to a lower extent than the unmodified siRNAs 
(94). 2´-NH2 modifications led to reduction in RNAi efficacy when placed in the 
passenger strand and drastic reduction in efficacy when placed in the guide strand (94). 
          In earlier studies, 2´-OMe substitutions (89) have been reported to drastically 
reduce RNAi effects. Fully 2´-OMe-substituted nucleoside containing siRNAs were not 
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functional, however two to four modifications in either strand were well tolerated. When 
every other nucleoside was modified with 2´-OMe, siRNAs were significantly resistant to 
serum nucleases (108). In another study, alternate placement of 2´-F and 2´-OMe 
modifications both in the guide and the passenger strands increased therapeutic efficacy 
of the siRNA (90). 2´-MOE (methoxyethyl) modifications were tolerated in the guide 
strand and alternate placement of 2´-MOE and 2´-OH or several 2´-MOE at the termini 
improved the RNAi activity (109). In general, the activity of 2´-sugar modifications in 
siRNAs depends on their size and position in the duplex; small modifications such as 2´-
F are generally well tolerated in the guide strand regardless of their position (92, 96). 
Larger 2´-OMe modifications are well tolerated at the 3´-end of the guide strands and at 
any positions in the passenger strands. Bulky 2´-MOE modifications are better placed in 
the passenger strands, whereas their inclusion in the guide strand generally decreases 
RNAi efficacy (92). 2´-F (88) and locked nucleic acid (LNA) (88) (containing a 
methylene bridge between the 2´ and the 4´ positions of the ribose) modifications are now 
frequently used to enhance nuclease resistance, thereby increasing the potency and 
decreasing the dosage of siRNA. 2´-F, LNA and ENA (ethylene-bridge nucleic acid) are 
known to restrict the sugar conformation and thereby enhance the specificity of 
complementary strand recognition and the strength of target binding. These two 
modifications, along with the 2´-F modification can increase the melting temperature 
(Tm) of siRNAs significantly (88). SiRNAs containing LNAs at the 5´-end 3´-end or both 
in the same strand can exhibit RNAi activity (88); however, LNA substitution at the 
central region of the siRNA leads to complete loss of activity. 
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           Substitution of the 4´-O with S has enhanced the Tm and the nuclease resistance of 
siRNA; 4´-S modified nucleosides are well tolerated at the termini of the both passenger 
and guide strands (110, 111). 4´-thio-2´-fluoroarabinonucleic acid (4´-S-2´-FANA) 
modifications, when placed into siRNAs, were able to mediate gene silencing through 
RNAi pathway; modifications at several sites afforded highly potent siRNAs (98). 
Alternate placement of 2´-FANA (2´-fluoroarabinonucleic acid) and 2´-FRNA  (2´-
fluororibonucleic acid) or LNA in an siRNA enhanced its potency (104). Recently the 
unlocked nucleic acid (UNA)-based sugar modifications were reported; these 
unrestrained groups can prevent sequence-dependent off-target effects at the expense of 
slight loss of efficacy (106). Few modifications of the sugar moiety have been reported in 
which the entire ribose group have been replaced by other groups as in the cyclohexenyl 
nucleic acid (CeNA), where one or two ribose moieties were replaced with cyclohexene 
moieties; resultant siRNAs retained their RNAi activity (112).   
          Backbone modifications. Phosphodiester backbone (88, 89, 94) modifications 
have improved several properties of the siRNA and made it more diverse as a therapeutic 
agent. Subtle phosphodiester backbone modifications, such as phosphorothioate (PS) and 
boranophosphate (BP) modifications, as well as complete replacement of the natural 
backbone with peptide or morpholino modifications have been reported (Figure 1.6). PS 
modifications are known to improve the ribonuclease resistance and pharmacokinetic 
profiles of the antisense oligonucleotides (113); these modifications are also known to 
bind with serum proteins and thereby enhance the half-life of the PS-modified antisense 
oligomers in the systemic circulation (114). Similar property enhancements might also be 
observed for siRNAs. However PS-modifications in the passenger strand or in the guide 
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strand lowers the Tm of the duplex (88) and reduces the RNAi efficacy (89) moderately. 
Fire and coworkers reported that phopsphorothioate substitution in both the guide and the 
passenger strands maintain RNAi effect in Caenorhabditis elegans (94). This reduction in 
RNAi potency may be associated with reduced binding interaction between the PS-
modified siRNAs and the RISC complex (100). Extensive substitution of the backbone 
with PS group has been proven to be cytotoxic; however moderate numbers of PS 
modifications have been tolerated in siRNAs (7). 
          In the boranophosphate modifications, one of the nonbridging oxygens is replaced 
with a borane (BH3) group. Enantiomerically pure boranophospate-substituted (BP) 
siRNAs are more nuclease resistant than racemic PS-substituted or unmodified siRNAs. 
BP modification slightly increases the Tm of the siRNA duplex and BP-modified siRNAs 
are more potent than PS-modified siRNAs. The BP-backbone is more lipophilic than the 
unmodified siRNAs and hence can have significant improvement in the pharmacokinetic 
and pharmacodynamic profiles of the BP-modified siRNAs compared to the unmodified 
ones. This modification is better tolerated in the passenger strand than in the guide strand 
and towards the termini of the oligonucleotides than the central region of the siRNA 
(115, 116). 
          In peptide nucleic acids (PNAs), the phosphodiester backbone is replaced by a 
peptide backbone. SiRNA-PNA chimeras at, or in place of the 3´ overhangs, have 
increased resistance to exonuclease digestion, siRNA half-life and RNAi efficacy (117). 
Morpholino (118) and triazolyl (119) modifications in those positions afforded similar 
results.  
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          Terminal modifications and bioconjugates. Polymer- (66, 82, 120), lipid- (121), 
cholesterol- (76, 122), carbohydrate- (66, 82), peptide- (123) and small molecule- (122) 
based terminal modifications and delivery systems of siRNAs exhibited effective RNAi; 
polymer- and cholesterol-based conjugates facilitated intracellular delivery of siRNA 
both in vitro and in vivo (46, 124) (Figures 1.7 and 1.8). For target specific delivery of the 
siRNA, suitable ligands (e.g., folic acid (81), mannose (82), hyaluronic acid etc.) are 
chemically attached at the termini of the strands. Small lipid-like molecules (lipidoids) 
when terminally attached to siRNAs can mediate RNAi in cultured cells and in animal 
models without the necessity of external delivery vehicles (74, 77). 
          Base modifications. SiRNA base modifications are relatively less explored 
compared to ribose modifications or terminal modifications because preservation of 
necessary H-bonding interactions and stable A-form duplex are crucial in effective RNAi 
(Figure 1.9) (9, 89, 125-131). Disruption of necessary H-bonding interactions (e.g. in N3-
Me-U) or steric occlusion of siRNA-RISC interactions (5-IU) can adversely affect the 
RNAi efficacy and specificity (89). For this reason, most of the successful base 
modifications have been introduced into either passenger strands or at the 3´-end of the 
guide strands (125, 129, 131). Base modifications have some additional advantages that 
cannot be matched by other chemical modifications; the importance of base pairing (126) 
at certain location in the siRNA can only be explored by suitable base modifications. 
Similarly, sterically demanding base modifications (e.g., triazolyl-containing click 
adduct) are tolerated at sites where even a small ribose modification (e.g., 2´-OMe) 
abolishes the RNAi activity completely (132). 
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         Effect of H-bonding on siRNA activity was explored by utilizing nucleobase 
isosteres in place of natural bases (Figure 1.9) (126, 127, 133). These moieties are 
hydrophobic and incapable of forming hydrogen bonds with natural nucleobases. Two 
hydrophobic isosteres of U, 2,4-difluorobenzene and 2,4-dichlorobenzene, when placed 
in different regions of the guide strand, enhanced thermal stability and maintained 
moderate RNAi efficacy when placed in the terminal regions of the siRNA. Similarly, 
2,4-difluorotoluene-containing siRNAs have enhanced nuclease stability and comparable 
RNAi activity (127). These modifications are well tolerated at position 7 of the guide 
strand, however when placed next to the mRNA cleavage site (position 10 or 11) RNAi 
efficacy is largely abolished (126, 127). 2,3-Dichlorobenzene and 4-methylbenz-
imidazole, even though unable to form H-bonds with other nucleosides, prefer U as the 
complementary base in the mRNA; steric similarity of those modifications with A might 
be a plausible explanation for this observation (133).  
          Mayer and coworkers reported that introduction of thermally destabilizing groups 
such as, 2,4-difluorotoluene, hypoxanthine, 5-nitroindole, purine, and 2-aminopurine at 
various positions within the passenger strand improved RNAi efficacy mainly due to 
thermal destabilization of the duplex (134). RNA major groove-modulating alkyl groups 
(methyl and propargyl) when substituted in U or C enhanced the thermal and nuclease 
stability of the siRNAs; however their effect on RNAi was dependent on the position and 
size of the modification (128). 2-Thiouracil or pseudouracil at the 3´-terminal of the 
guide strand increases the RNAi efficacy when a single dihydrouracil is also placed at the 
3´-end of the passenger strand (135); this enhancement in efficacy can be attributed to 
increased duplex asymmetry and facilitated strand unzipping from the 5´-end (135). 
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          6-Phenylpyrrolocytosine, a highly fluorescent nucleoside analog, when placed in 
the passenger strand or towards the 3´-terminal of the guide strand, silenced target genes 
efficiently and helped visualize intracellular trafficking (131). Minor-groove-modulating 
guanine and 2-aminopurine modifications have been reported to reduce off-pathway 
protein interaction (125, 129, 130). Mikat and Heckel investigated the use of the 
photolabile 2-(2-nitrophenyl)propyl  group as a temporary major groove modification of 
U  or G  in the guide and passenger strands of the siRNA; but those modifications were 
found to be fully effective only at a single site (136) . 
 
Conclusion 
          The therapeutic potential of siRNA has not yet been exercised fully, mainly due to 
lack of appropriate delivery vehicles and numerous off-target effects. To address 
limitations of siRNA, chemical modifications of different segments of the siRNA are a 
potential solution. Although ribose modifications are most extensively studied, backbone 
and terminal modifications have also been explored. Terminal modifications of siRNA 
strands have served multiple purposes, e.g., intracellular delivery, enhancement of siRNA 
half-life, improving bio-distribution and pharmacokinetic profiles. Although not as 
common, successful base modifications have been reported both in the passenger and the 
guide strands. Base modifications provide valuable information regarding necessity of 
base pairing at certain regions of the siRNA, the scope of modification as applied to A, 
U, G, and C, the structure of the major and minor grooves during delivery and in the 
RISC and prevention of off-pathway protein binding.  
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8-ALKOXYADENOSINES AS POTENTIAL MODULATORS  
 
OF OFF-PATHWAY PROTEIN BINDING 
 
 
Introduction           
          SiRNA-based RNAi pharmaceuticals are gradually becoming a principal 
alternative to small molecule-based drugs. Theoretically, any malfunctioning gene (and 
the related disease) can be targeted by this technique; even so called ‘nondruggable’ 
targets can be reached by siRNAs. RNAi is still a relatively new technology, and within a 
short time period significant advancement has been made to bring this technique from the 
research laboratory to the clinic.  
          However, the therapeutic potential of siRNA has not yet been maximized mainly 
due to delivery problems and undesired side effects, such as sequence-dependent off-
target effects, sequence-specific and sequence-independent off-pathway protein binding 
leading to innate immune responses. Although not as pronounced as the long dsRNAs, 
siRNAs can induce an innate immune response. SiRNAs are recognized by the 
intracellular defense mechanism as a potential viral infection; and the genes related to the 
innate immune system (such as INFα, 2´,5´-oligoadenylate synthase (OAS) and signal 
transducers/activators of transcription) are upregulated leading to immunostimulation (1, 
2). These side effects can mask or even counter RNAi efficacy and specificity. Due to 
these off-target effects and off-pathway protein binding, the therapeutic dosage of the 
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siRNA must be increased significantly leading to dsRNA-related toxicity. Hence, 
prevention of these undesired side effects is essential. 
          Off-target gene silencing. Initially, siRNA was thought to be an extremely 
selective method of gene silencing; it was thought to be only functional if there was a 
perfect complementarity between the guide strand and the mRNA. Several studies have 
claimed that even a single mismatch with the mRNA completely abolished the RNAi 
activity (4). 
          However, it was gradually understood that siRNA could silence genes, partially or 
extensively, even when there is partial complementarity between the siRNA and the 
mRNA. Jackson et al. reported that this kind of miRNA-like effects could originate when 
any region of an mRNA is complementary to the seed region (bases at positions 2-8) of 
the guide siRNA (5-7). One probable solution to this ‘off-target’ effect is to select a 
different siRNA, the seed region of which is only complementary to the target mRNA. 
Sometimes this might not be trivial because many other parameters should also be 
satisfied to design a successful siRNA.  
          Another alternative is to chemically modify specific positions of the seed region to 
reduce the off-target effects. A 2´-OMe modification in the seed region significantly 
lowered the sequence-dependent off-target effects. This modification, when placed in 
position 2, is more effective than any other positions (5). Bramsen et al. reported several 
ribose modifications that are effective in preventing the sequence-dependent off-target 
effect; their study revealed that the UNA modification is the most effective modification 
out of ten different modifications (Figure 2.1) (8). The UNA modification weakens the 
siRNA-mRNA interaction moderately, without lowering the RNAi efficacy considerably. 
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          Sequence-specific immunostimulation. Analogous to 5´-CpG-3´ containing DNA 
oligonucleotides (9), certain siRNA sequences are also immunostimulatory. GU-rich 
siRNA sequences produces Interferon-α (INFα) which upregulates INFα-associated genes 
in human peripheral blood mononuclear cells (PBMCs), plasmacytoid dendritic cells 
(PDCs) isolated from human peripheral blood, as well as in CD4+ 4 and CD8+ T cells in 
mice (10, 11). In these cases, immunostimulation occurs through interaction of Toll-like 
receptor 7 (TLR7) with certain sequence motifs in the guide or the passenger strand.  
          The mechanism of TLR-mediated immunostimulation due to siRNA binding is 
currently unknown. Several ribose modifications such as 2´-OMe, LNA, 2´-F-RNA, 2´-F-
ANA, are known to prevent TLR-mediated immunostimulation (Figure 2.2) (10, 12, 13). 
To date, no base modification has been reported to address this off-pathway interaction. 
The TLR7-mediated innate immune response is sequence-dependent, so recognition of 
specific nucleoside motifs (such as GU-rich siRNAs) might be prevented by appropriate 
base modifications.  
          Sequence-independent off-pathway protein binding and immunostimulation. 
SiRNAs, irrespective of their sequences, can bind with proteins that are not directly 
involved in the RNAi pathway (1, 14). Among these proteins, an important class contains 
double-stranded RNA binding motif (dsRBM) containing domains, which can be used to 
bind duplex RNAs longer than 16 base pairs. Some important members of this group of 
proteins are RNA-dependent protein kinase (PKR) (Figure 2.3) and adenosine 
deaminases that modify RNA (ADARs), RNA helicase A, and Staufen1, an RNA 
trafficking protein. Duplex RNAs are also ligands of TLR3 and OAS and naturally can 
also interact with siRNA (2, 15).  TLRs are a group of proteins that recognize molecular 
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scaffolds related to pathogenic infection and initiate immune response (15). OAS can be 
stimulated upon binding with siRNA and nonspecific Ribonuclease L is activated as a 
part of the innate immune response to viral infection (16). 
           PKR and ADAR1 have been reported to bind with siRNAs complicating RNAi 
experiments (1, 14). ADAR1 binds with the siRNA and reduces its effective 
concentration in cell, affecting RNAi efficacy significantly (14). PKR is a crucial 
component for controlling translation initiation and signal transduction; upon binding 
with siRNA, PKR sends signals analogous to viral infection and instigates interferon-
mediated immunostimulatory response, which finally leads to cell apoptosis (Figure 2.3). 
Activation of PKR also induces global expression of PKR-associated genes in the human 
glioblastoma cell line (1).  
          Nucleobase modifications to prevent the siRNA-PKR interaction. Prevention of 
these sequence-independent off-pathway protein interactions is essential for the potency 
and specificity of therapeutic siRNA. The Beal laboratory initiated a systematic study on 
base modifications of the siRNA to address and alleviate siRNA-PKR interaction (17, 
18). During PKR-binding studies with stem-loop IV of EBER1 (an RNA from Epstein-
Barr virus), they noticed that substitution of some specific guanosines with N2-
benzylguanosine could greatly diminish PKR-EBER1 interaction. It was also realized 
that this strategy of ‘steric occlusion of the minor groove’ could be utilized to address 
siRNA off-target effects (Figure 2.4).  
          Their hypothesis was experimentally verified when modifications at several 
positions (6, 9, 11, 14) of the sense strand of caspase 2 siRNA successfully prevented 
PKR binding (Figure 2.4) (18).  These N2-benzylguanosine analogs maintained normal  
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hydrogen-bonded base pairing while projecting sterically demanding moieties in the 
minor groove; thereby preventing binding of dsRBM (of PKR) onto minor grooves of 
siRNA duplexes (Figure 2.5). Peacock et al. have shown (Figure 2.4) that pendent minor 
groove modifications of 2-aminopurines (20) in the passenger caspase 2 siRNA can also 
successfully prevent siRNA-PKR interaction, while maintaining RNAi efficacy.  
          Similar modifications of the minor or major groove in the guide strand might serve 
multiple purposes, such as preventing PKR or ADAR1 binding and elucidating novel 
mechanistic features of siRNA-RISC interactions while maintaining RNA interference 
activity. However, siRNA base modifications in the guide strand are more challenging; 
Some base modifications drastically reduced or completely abolished the RNAi efficacy 
when placed at crucial siRNA sites, such as in the seed region or at the cleavage site.  
           N2-Alkylated 2´-deoxy-7,8-dihydro-8-oxoguanosine containing siRNAs could 
prevent siRNA-PKR interaction significantly by placing a ‘switchable’ alkyl group in the 
minor groove of an siRNA during delivery; in the RISC, the modified siRNAs can flip its 
steric bulk into the major groove, and maintain good siRNA efficacy (Figure 2.6) (21). 
However, oxidized purine lesions, such as 2´-deoxy-7,8-dihydro-8-oxoguanosine, are 
known to be immunostimulatory themselves. Therefore exploring other purine 
modifications in the guide strand is worthwhile and essential. Here, we report a series of 
novel nucleobase modifications, 8-alkoxyAs and their potential application in the RNAi. 
          8-AlkoxyA phosphoramidites were synthesized and incorporated into the guide 
strand of a caspase 2 siRNA through solid phase oligonucleotide synthesis. Modified 
siRNAs were tested for their RNAi efficacy and ability to address off-target effects due to 
siRNA-PKR interactions.  






Figure 2.5. Sites of the siRNA passenger strand modifications to prevent PKR binding.  
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Figure 2.6. ‘Switchable’ N2-alkylated 2´-deoxy-7,8-dihydro-8-oxoguanosines in duplex 
RNA to prevent PKR binding: (A) cartoon (B) base-pairs. (adapted and reproduced with 
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          8-Substituted adenosines and guanosines have been shown to exist in an 
equilibrium mixture of syn/anti conformations. Accordingly, 8-alkoxyadenosines are 
postulated to have a tendency to flip between anti and syn conformations, depending on 
the base-pairing partner. In the natural anti conformation, 8-alkoxyA will base pair with 
U, whereas, in the syn conformation, the Hoogsteen face of the nucleoside will be 
exposed for base pairing and it will complement best with anti G (Figure 2.7). We 
propose that during delivery of the siRNA, 8-alkoxyA in the guide strand (opposite to G 
in the passenger strand) would project its steric blockade into the minor groove of 
siRNA, thereby preventing intracellular protein binding onto the RNA. When the siRNA 
is recruited into the RISC assembly, the 8-alkoxyA in the guide siRNA would encounter 
U in the mRNA and would flip its steric bulk into the major groove, thereby allowing 
necessary guide strand-mRNA-RISC assembly to form (Figure 2.8). 
          Alkyl groups were chosen based on their size and shape: propargyl, phenethyl and 
cyclohexylethyl. The rationale behind the choices is that: smaller groups (propargyl) 
might exhibit higher duplex stabilities and better mRNA knock down efficiencies 
whereas larger group (cyclohexylethyl) might prevent immunostimulation to a greater 
extent, and a medium-sized group (such as phenethyl) might serve both the purposes 
equally efficiently. 
          Synthesis of the 8-alkoxyadenosine phosphoramidites. 8-Alkoxyadenosine 
phosphoramidites were synthesized in multiple steps from a ribose-protected 8-
bromoadenosine derivative. Here it is outlined briefly, and the detailed step- by-step 
synthesis can be found in the Experimental section below. Adenosine was first 
brominated at C8 following a published procedure and the hydroxyl groups of the ribose 
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Figure 2.8. Proposed base ‘switch’ cartoon to prevent off-pathway protein interaction 
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moiety were protected by silylating agents. 5´-OH and 3´-OH groups were protected 
using a bidentate silylating agent and the remaining 2´-OH was protected using a 
TBDMS protecting group.  Next, the bromine was displaced with an alkoxy groups that 
was generated in situ by adding dropwise n-BuLi into the corresponding alcohol in THF. 
The exocyclic amine of adenosine was protected using a benzoyl group. Then, the 5´-OH 
and 3´-OH were deprotected using pyridine-HF reagent, leaving the 2´-O-protection 
intact. For application in the automated solid phase oligonucleotide synthesis, the 5´-OH 
was protected with a DMT group, and the 3´-OH was coupled to a phosphoramidite 
group (Figure 2.9).  
 
Experimental 
           All the chemicals were obtained commercially, unless otherwise stated, and used 
without further purification. Freshly distilled solvents were used where anhydrous 
solvents were required. THF was distilled from Na metal and benzophenone. For TLC, 
Merck silica gel 60 F254 pre-coated plates were used. Glassware for all the reactions was 
dried overnight in the oven at 150 °C and cooled in desiccators. Silica gel 60 (230-400 
mesh) was used for flash chromatographic purpose. Column fractions were carried out as 
mentioned in the separation of individual compounds. 1H, 13C, and 31P NMR spectra were 
recorded at 300, 75, and 121 MHz, respectively. Chemical shift values are reported in 
parts per million (ppm) using the solvent peak as the reference. In interpreting the 1H 
NMR peak multiplicities, s, d, dd, t, q, m, and brs abbreviations were used for singlet, 
doublet, doublet of doublets, triplet, quartet, multiplet, and broad singlet, respectively. 
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          8-Bromoadenosine (1). 8-Bromoadenosine was synthesized following a literature 
procedure (22). Product yield was 82.5%: melting point >200 °C; 1H NMR (300 MHz, 
d6-DMSO) δ 8.12 (s, 1H, 2-H), 7.56 (s, 2 H, 6-NH2), 5.80-5.84 (d, 1H, 1´-H), 5.42-5.52 
(m, 2H, 2´- and 3´-OH), 5.20-5.25 (d, 1H, 5´-OH), 5.03-5.12 (q, 1H, 2´-H), 4.17-4.22 
(brs, 1H,  3´-H), 3.94-4.00 (m, 1H, 4´-H), 3.62-3.72 (m, 1H, 5´-H),  3.46-3.56 (m, 1H, 5´-
H). 13C NMR (75 MHz, d6-DMSO): δ 155.2, 152.4, 149.8, 127.2, 119.6, 90.4, 86.7, 71.1, 
70.9. HRMS: calcd for C10H12N5O4Na79Br [MNa+] 367.9970, obsd 367.9973. 
          5´,3´-O-Bis(-t-butylsilyl)-2´-O-(t-butyldimethylsilyl)-8-bromoadenosine(3). 
Both the 3´-OH and 5´-OH were protected by a designer protecting group introduced by 
Trost and coworkers (23). In an oven-dried flask 1 mmol (346 mg) of 1 was suspended in 
5 mL anhydrous DMF. The suspension was cooled down to 0 °C and 1.1 equivalent (400 
µL) di-t-butylsilyl ditriflate was added drop wise under stirring condition, at the same 
temperature. The reaction was carried out under N2 atmosphere for 30 min and after that 
time period no starting material was detected, when the reaction mixture was analyzed 
using TLC. After synthesis of the intermediate 2, the reaction was quenched immediately 
with 5 equivalents (344 mg) of imidazole at 0 °C. The reaction was stirred at the same 
temperature for 5 additional min, and then the system was allowed to equilibrate to room 
temperature. Then, 1.2 equivalents (181 mg) of t-butyldimethylsilyl chloride were added 
and a reflux condenser was connected to the reaction flask. The temperature was elevated 
to 60 °C, and the reaction was run overnight under nitrogen. The suspension was cooled 
down to room temperature, water was added and the precipitate was collected by suction 
filtration. The supernatant was discarded, and then the white precipitate was rewashed 
with cold methanol (4 °C) to obtain pure compound 3. The methanol layer was 
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evaporated under reduced pressure and a simple column separation (5:1 hexane:ethyl 
acetate) could separate the remaining product. Overall yield of the product was 590 mg 
(98%): silica gel TLC Rf  0.44 (3:2 hexane:ethyl acetate); 1H NMR (300 MHz, CDCl3): δ 
8.25 (s, 1H, 2-H), 6.55 (s, 2 H, 6-NH2), 5.89-5.92 (d, 1H, 1´-H), 5.15-5.24 (q, 1H, 2´-H), 
4.86-4.92 (d, 1H,  3´-H), 4.33-4.42 (dd, 1H, 4´-H), 3.95-4.14 (m, 2H, 5´-H), 1.16 (s, 9H, 
(CH3)3), 1.03 (s, 9H, (CH3)3), 0.88 (s, 9H, (CH3)3), 0.11 (s, 3H, CH3), 0.07 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3): δ 154.9, 153.3, 150.7, 127.6, 120.5, 94.2, 75.2, 74.6, 67.7, 
27.8, 27.3, 26, 23, 20.5, 18.6, -4.2, -5.0.  HRMS: calcd for C24H42N5O4NaSi279Br [MNa+] 
622.1856, obsd 622.1850. 
          5´,3´-O-Bis(t-butylsilyl)-2´-O-(t-butyldimethylsilyl)-8-propargyloxyadenosine 
(4). Propargyloxy anion was generated in situ by allowing n-BuLi to react with excess 
anhydrous propargyl alcohol. 0.83 mmol (500 mg) of compound 4 was dissolved in 2 mL 
anhydrous THF in a round bottom flask under argon gas. Anhydrous propargyl alcohol (1 
mL) was added to 4 mL freshly distilled THF in a reaction flask fitted with a balloon; the 
solution was kept under nitrogen atmosphere and cooled down to -40 °C. Then, 10 mmol 
n-BuLi (3.5 ml of 2.5M hexane solution) was gradually added to the reaction mixture; the 
by-product butane was collected in a balloon. The reaction was completed instantly. This 
in situ generated lithium propargyloxide was transferred to the flask containing 4 through 
an oven-dried syringe. The reaction was allowed to proceed for 20 h at room temperature. 
TLC monitoring indicated the absence of any 4 after that time period. The solution was 
neutralized by dilute acetic acid. Excess solvent was removed under reduced pressure and 
the solid residue was then partitioned between water and ethyl acetate. The ethyl acetate 
layer was collected and dried by using anhydrous Na2SO4. Flash chromatography was 
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used to elute (2:3 hexane:ethyl acetate) the desired compound, 4.  Yield of 4 was 94%; 
silica gel TLC Rf  0.24 (2:3 hexane:ethyl acetate);1H NMR (300 MHz, CDCl3):    δ 8.21 
(s, 1H, 2-H), 5.93 (d, 1H, 1´-H), 5.61(s, 2H, NH2), 5.05-5.20 (m, 2H, CH2)  4.91-4.97 (q, 
1H, 2´-H), 4.66-4.71 (d, 1H,  3´-H), 4.34-4.45 (m, 1H, 4´-H), 4.02-4.12 (m, 2H, 5´-H), 
2.61-2.65 (t, 1H, CH), 1.00-1.20 (d, 18H, (CH3)3), 0.89 (s, 9H, (CH3)3), 0.11 (d, 6H, 
2CH3). 13C NMR (75 MHz, CDCl3): δ 153.7, 153.2, 151.8, 149.8, 116.0, 90.5, 75.3, 74.8, 
74.7, 67.9, 58.0, 27.8, 27.2, 26.1, 22.9, 20.7, 18.8, -4.2, -4.9. HRMS: calcd for 
C27H46N5O5Si2 [MH+] 576.3038, obsd 576.3030.  
           5´,3´-O-Bis(t-butylsilyl)-2´-O-(t-butyldimethylsilyl)-N6-benzoyl-8-propargyl-
oxyadenosine (5). The N6-amino group of 4 was protected using benzoyl chloride 
(BzCl). 0.77 mmol (435 mg) of 4 was dissolved in 2 mL anhydrous pyridine in a reaction 
flask and the solution was cooled down to -5 °C (by using salt-ice bath). Two equivalents 
of BzCl (1.54 mmol, 181µL) were added dropwise using a disposable syringe while 
stirring. The reaction mixture was allowed to warm to room temperature over a period of 
1 h, and the reaction was continued for 4 h under argon. After that time, excess benzoyl 
chloride was quenched with 1 mL methanol. The reaction was allowed to stand for an h 
at 0 °C. Then, excess methanolic ammonia (1 mL 7N NH3) was added and the solution 
was stirred for an additional hour at the same temperature. The crude product mixture 
was then dried down under reduced pressure to a solid residue, which was first 
partitioned between ether and saturated NaHCO3 solution. The organic layer was then 
washed several times with water and, subsequently, dried with anhydrous Na2SO4. 
Product was then separated (3:1 hexane:ethyl acetate) by flash chromatography. Yield of 
the product 5 varied between 89% to 95%; silica gel TLC Rf  0.62 (2:3 hexane:ethyl 
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acetate); 1H NMR (300 MHz, CDCl3): δ 8.70-8.78 (bs, 1H, CONH-), 8.63 (s, 1H, 2-H), 
7.95-8.02 (m, 2H, PhCO), 7.48-7.65 (m, 3H, PhCO), 5.91 (s, 1H, 1´-H), 5.13-5.29 (m, 
2H, CH2), 4.86-4.95 (q, 1H, 2´-H), 4.68-4.74 (d, 1H, 3´-H), 4.35-4.47 (m, 1H, 4´-H),  
4.03-4.16 (m, 2H, 5´-H), 2.60-2.63 (t, 1H, CH), 1.13 (s, 9H, (CH3)3), 1.05 (s, 9H, 
(CH3)3), 0.90 (s, 9H, (CH3)3), 0.07-0.15, (d, 6H, CH3). 13C NMR (75 MHz, CDCl3): δ 
164.9, 154.9, 153.1, 151.3, 146.7, 134.2, 132.8, 129.1, 128.0, 120.5, 90.7, 75.5, 75.0, 
67.8, 58.8, 27.8, 27.3, 26.1, 22.9, 20.6, 18.7, -4.2, -4.9. HRMS: calcd for C34H50N5O6Si2 
[MH+] 680.3300, obsd 680.3297.    
           2´-O-t-Butyldimethylsilyl-N6-benzoyl-8-propargyloxyadenosine(6). Compound 
5 was selectively deprotected at 5´-OH and 3´-OH by using (HF)x.py at subzero 
temperature. 0.74 mmol (505 mg) of 5 was added in CH2Cl2 and the solution was cooled 
down to -15 °C. 3.7 mmol (0.1 mL) of of (HF)x•py was diluted with 600 µL pyridine at 0 
°C. The latter solution was then gradually added to the former solution and the reaction 
temperature was maintained at -15 °C. The reaction was complete in 2-2.5 h. 50 ml 
CH2Cl2 was added to the product mixture. The solution was then washed with saturated 
aqueous NaHCO3 solution. CH2Cl2 layer was then washed several times with water and 
dried with anhydrous Na2SO4. Pure product was obtained by flash chromatography (3:7 
hexane:ethyl acetate). Yield of the desired product 6 was 82% to 95%; silica gel TLC Rf  
0.13 (2:3 hexane:ethyl acetate);1H NMR (300 MHz, CDCl3): δ 8.99 (s, 1H, CONH-), 
8.6(s, 1H, 2-H), 7.91-7.98 (m, 2H, PhCO), 7.42-7.58 (m, 3H, PhCO), 5.94-6.02 (d, 1H, 
5´-OH), 5.89-5.93 (d, 1H, 1´-H), 5.12-5.16 (m, 2H, CH2), 5.03-5.09 (m, 1H, 2´-H), 4.27-
4.32 (m, 2H, 3´-H  and 4´-H), 3.85-3.93 (bd, 1H, 5´-H), 3.64-3.74 (bt, 1H, 5´-H), 2.94 (s, 
1H, 3´-OH), 2.60-2.64 (t, 1H, CH), 0.76 (s, 9H, (CH3)3), -0.18 (s, 3H, CH3), -0.37 (s, 3H, 
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CH3). 13C NMR (75 MHz, CDCl3): δ 164.7, 155.2, 150.9, 150.5, 147.4, 133.9, 132.7, 
128.9, 127.8, 120.4, 87.9, 87.3, 76.3, 73.9, 72.7, 63.4, 58.4, 25.8, 17.8, -5.2, -5.3. HRMS: 
calcd for C26H34N5O6Si [MH+] 540.2278, obsd 540.2277. 
          5´-O-(4,4´-Dimethoxytrityl)-2´-O-(t-butyldimethylsilyl)-N6-benzoyl-8-proparg-
yloxyadenosine (7). 0.204 mmol (110 mg) of compound 6 was dissolved in 2 mL 
anhydrous pyridine. The solution was cooled down to 0 °C under argon and 1.2 
equivalent (85 mg) of DMT-Cl was added. The reaction mixture was stirred for 4 h at 0 
°C and then for 6 h at room temperature. Then 1.2 equivalent of the DMT-Cl reagent was 
again added to the reaction mixture at 0 °C and the reaction was allowed to continue 
overnight. The reaction was quenched by addition of excess anhydrous methanol (0.5 
mL). After another hour at room temperature, the solution was concentrated to dryness 
under reduced pressure. The crude solid was first fractioned between aqueous NaHCO3 
and ethyl acetate, and then the organic layer was washed several times with water. A 
short chromatography column (2:3 hexane:ethyl acetate) was necessary to purify the 
product. Yield of the product 7 varied from 75% to 80%; silica gel TLC Rf  0.47 (2:3 
hexane : ethyl acetate); 1H NMR (300 MHz, CDCl3): δ 8.91 (s, 1H, CONH-), 8.5 (s, 1H, 
2-H), 7.94-8.02 (m, 2H, PhCO), 7.14-7.6 (m, 12H, Ph), 6.74-6.81 (dd, 4H, Ph), 5.97-6.03 
(d, 1H, 1´-H), 5.0-5.20 (dq, 2H, CH2), 4.39-4.44 (t, 1H, 2´-H),  4.18-4.24 (q, 1H, 3´-H), 
4.07-4.15 (q, 1H, 4´-H),  3.75 (s, 6H, OCH3), 3.45-3.52 (m, 1H, 5´-H),  3.28-3.37 (dd, 
1H, 5´-H), 2.78-2.84 (d, 1H, 3´-OH), 2.54-2.58 (t, 1H, CH), 0.83 (s, 9H, (CH3)3), -0.01 (s, 
3H, CH3), -0.17 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3): δ 165, 158.6, 155.7, 152.4, 
151.2, 146.8, 145.1, 136.3, 136.1, 134.3, 132.8, 130-130.4 (d), 129.1, 128.4, 128, 127, 
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120, 113, 87.2, 86.5, 84, 72.8, 71.6, 63.8, 58.6, 55.4, 25.8, 18, 14.4, -4.6, -4.8. HRMS: 
calcd for C47H51N5O8SiNa [MNa+] 864.3405, obsd 864.3405.  
          5´-O-(4,4´-Dimethoxytrityl)-3´-O-[(2-cyanoethoxy)(N,N-diisopropylamino)ph-
osphino]-2´-O-(t-butyldimethylsilyl)-N6-benzoyl-8-propargyloxyadenosine (8). 8-
Propargyloxyadenosine phosphoramidite was synthesized using the 2-cyanoethyl N,N-
diisopropylchlorophosphoramidite reagent. 0.178 mmol (150 mg) of compound 7 (was 
dissolved in 5 mL of freshly distilled THF contained in an oven-dried flask. Five 
equivalent (0.9 mmol, 205 µL) DIPEA was added and the solution was stirred for 5 min 
at room temperature (23 °C), and then cooled down to 0 °C, under argon atmosphere. 81 
µL (0.36 mmol, 2 equivalent) of phosphoramidite was added dropwise into the flask. 
Reaction was stirred at 0 °C for 30 min and then gradually warmed up to room 
temperature. After another hour under inert atmosphere, the solvent was evaporated by 
rotary evaporation and the desired product was separated by silica gel column chromato-
graphy (11:9 hexane:ethyl acetate). Yield of 8 varied from 82% to 90%; silica gel TLC Rf  
0.47 (2:3 hexane:ethyl acetate); 1H NMR (300 MHz, CDCl3): 8.76-8.82 (d, 1H, CONH-), 
8.44-8.52 (d, 1H, 2-H), 7.94-8.02 (m, 2H, PhCO), 7.14-7.62 (m, 12H, Ph), 6.74-6.82 (m, 
4H, Ph),  5.95-6.02 (t, 1H, 1´-H), 5.29-5.40 (m, 1H, 2´-H), 5.02-5.4 (m, 2H, CH2), 4.3-
4.55 (m, 2H, 3´-H and 4´-H),  4.07-4.24 (q, 1H, 5´-H), 3.78-4.02 (m, 1H, 5´-H),  3.75 (s, 
6H, OCH3), 3.51-3.68 (m, 4H, CH2CN, 2CHN), 2.64-2.70 (m,1H,P-O-CH2), 2.50-2.56 (t, 
1H, CH), 2.28-2.34 (m, 1H, P-O-CH2), 1.14-1.3 (m, 12H, 4CH3), 0.70-0.80 (d, 9H, 
(CH3)3), (-0.08)-0.0 (d, 3H, CH3),(-0.34)-(-0.20) (s, 3H, CH3). 13C NMR (75 MHz, 
CDCl3): δ 164.8, 158.6, 156, 155.9, 152.4, 152.3, 151.2, 146.8, 145.1, 144.9, 136.4-
136.1(m), 134.4, 132.8, 130.4, 129.1, 128.5, 127, 120.1, 117.6, 117.9, 113.3, 86.4-87.0 
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(q), 84.0 (d), 72-73.8 (m), 63.4-63.8(d), 60.8, 59.0-59.4, 58.4, 57.8-58.4, 55.5, 43.5-43.8 
(d), 43.0-43.4 (m), 25.9, 24.7-25.2 (m), 22.8, 23.4, 21.4, 20.7, 20.3, 18.2, 14.5, -4.3, -4.8. 
31P NMR (CD2Cl2): 149.7, 151.8. HRMS: calcd for C56H68N7O9SiPNa [MNa+] 
1064.4483, obsd 1064.4493.  
          All phenylethoxyadenosine and cyclohexylethoxyadenosine derivatives were 
prepared following procedures analogous to those used for the propargyloxyadenosine 
derivatives.  
          5´,3´-O-Bis(t-butylsilyl)-2´-O-(t-butyldimethylsilyl)-8-phenylethoxyadenosine 
(9). Yield 97%; silica gel TLC Rf  0.32 (1:1 hexane:ethyl acetate); 1H NMR (300 MHz, 
CDCl3): δ 8.19 (s, 1H, 2-H), 7.23-7.36 (m, 5H, Ph), 5.85 (s, 1H, 1´-H), 5.52 (s, 2H, NH2), 
4.90-4.98 (q, 1H, 2´-H), 4.67-4.76 (m, 3H, 3´-H, OCH2), 4.34-4.41 (m, 1H, 4´-H), 3.95-
4.10 (m, 2H, 5´-H), 3.12-3.2 (t, 2H, CH2), 1.00-1.16 (d, 18H, (CH3)3), 0.87 (s, 9H, 
(CH3)3), 0.02-.10 (d, 6H, 2CH3). 13C NMR (75 MHz, CDCl3): δ 154.2, 153.4, 151.5, 
149.8, 116.0, 90.5, 75.5, 74.6, 71.1, 67.9, 35.2, 27.6, 27.2, 26.1, 22.9, 20.7, 18.6, -4.2, -
4.9.  
          5´,3´-O-Bis(t-butylsilyl)-2´-O-(t-butyldimethylsilyl)-N6-benzoyl-8-phenylethox-
yadenosine (10). Yield 80-92%; silica gel TLC Rf  0.67 (2:3 hexane:ethyl acetate); 1H 
NMR (300 MHz, CDCl3): δ 8.80-8.88 (bs, 1H, CONH-), 8.59 (s, 1H, 2-H), 7.94-8.02 (m, 
2H, PhCO), 7.46-7.62 (m, 3H, PhCO), 7.24-7.36 (m, 5H, Ph), 5.91 (s, 1H, 1´-H), 4.88-
4.96 (dd, 1H, 2´-H), 4.76-4.84 (t, 2H, CH2), 4.68-4.74 (d, 1H, 3´-H), 4.35-4.42 (q, 1H, 4´-
H), 3.95-4.13 (m, 2H, 5´-H), 3.13-3.22 (t, 2H, CH2), 1.2 (s, 9H, (CH3)3), 1.05 (s, 9H, 
(CH3)3), 0.89 (s, 9H, (CH3)3), 0.03-0.11 (d, 6H, 2CH3). 13C NMR (75 MHz, CDCl3): δ 
165, 156, 152, 151, 146.4, 137, 134.3, 132.8, 129, 128.0, 127 121, 90.6, 75.5, 74.5, 71.8, 
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67.8, 35.2, 27.8, 27.3, 26.1, 23, 20.7, 18.7, -4.2, -4.9. HRMS: calcd for C39H55N5O6NaSi2 
[MNa+] 768.3589, obsd 768.3600. 
          2´-O-t-Butyldimethylsilyl-N6-benzoyl-8-phenylethoxyadenosine (11). Yield 88-
94%; silica gel TLC Rf  0.12 (2:3 hexane:ethyl acetate); 1H NMR (300 MHz, CDCl3): δ 
8.88 (bs, 1H, CONH-), 8.62 (s, 1H, 2-H), 7.94-8.0 (m, 2H, PhCO), 7.44-7.62 (m, 3H, 
PhCO), 7.22-7.34 (m, 5H, Ph), 5.98-6.06 (d, 1H, 5´-OH), 5.87-5.92 (d, 1H, 1´-H), 5.07-
5.14 (m, 1H, 2´-H), 4.62-4.82 (m, 2H, CH2), 4.29-4.35 (d, 2H, 5´-H), 4.05-4.13 (q, 1H, 
3´-H), 3.87-3.97 (d, 1H, 4´-H), 3.10-3.18 (t, 2H, CH2), 2.90 (s, 1H, 3´-OH), 0.77 (s, 9H, 
(CH3)3), -0.16 (s, 3H, CH3), -0.40 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3): δ 164.7, 
156.2, 151, 150.5, 147.2, 136.9, 134.2, 133, 129, 127.2, 121, 87.4-88 (d), 72-74 (t), 35.4, 
25.7, 17.8, -5.0, -5.3. HRMS: calcd for C31H39N5O6NaSi [MNa+] 628.2567, obsd 
628.2575.  
          5´-O-(4,4´-Dimethoxytrityl)-2´-O-(t-butyldimethylsilyl)-N6-benzoyl-8-phenyl-
ethoxyadenosine (12). Yield 68-81%; silica gel TLC Rf  0.6 (2:3 hexane:ethyl acetate); 
1H NMR (300 MHz, CDCl3): δ 8.68 (bs, 1H, CONH-), 8.47 (s, 1H, 2-H), 7.94-8.02 (m, 
2H, PhCO), 7.42-7.62 (m, 5H, Ph), 7.14-7.38 (m, 12H, Ph), 6.72-6.8 (dd, 4H, Ph), 5.87-
5.92 (d, 1H, 1´-H), 5.26-5.32 (m, 1H, 2´-H), 4.66-4.80 (M, 2H, CH2), 4.32-4.4.38 (q, 1H, 
3´-H), 4.16-4.22 (q, 1H, 4´-H), 3.75 (s, 6H, OCH3), 3.28-3.5 (m, 2H, 5´-H), 3.04-3.12 (t, 
2H, CH2), 2.71-2.75 (d, 1H, 3´-OH), 0.80 (s, 9H, (CH3)3), -0.07 (s, 3H, CH3), -0.23 (s, 
3H, CH3). 13C NMR (75 MHz, CDCl3): δ 171.3, 164.9, 158.5, 156.5, 152.2, 151, 146.3, 
145.1, 136.9, 136.1, 136.2, 134.4, 132.8, 130.3, 128.9-129.1 (d), 128.5, 127.1, 127, 121, 
113, 87.2, 86.4, 84, 72.5, 71.8, 71.6, 63.9, 60.7, 55.4, 35.3, 25.8, 21.4 18, 14.5, -4.78, -
4.88  HRMS: calcd for C52H57N5O8NaSi [MNa+] 930.3874, obsd 930.3867.  
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          5´-O-(4,4´-Dimethoxytrityl)-3´-O-[(2-cyanoethoxy)(N,N-diisopropylamino)pho-
sphino]-2´-O-(t-butyldimethylsilyl)-N6-benzoyl-8-phenylethoxyadenosine(13). Yield 
82-86% silica gel TLC Rf  0.6 (2:3 hexane:ethyl acetate); 1H NMR (300 MHz, CDCl3): 
8.66 (s, 1H, CONH-), 8.40-8.46 (d, 1H, 2-H), 7.96-8.02 (m, 2H, PhCO), 7.42-7.62 (m, 
5H, Ph), 7.20-7.39 (m, 12H, Ph), 6.74-6.82 (m, 4H, Ph), 5.88-5.94 (t, 1H, 1´-H), 5.36-
5.46 (m, 1H, 2´-H), 4.68-4.78 (m, 2H, OCH2), 4.30-4.54 (m, 2H, 3´-H and 4´-H), 3.82-
4.02 (m, 1H, 5´-H), 3.76 (s, 6H, OCH3), 3.51-3.70 (m, 4H, CH2CN, 2CHN), 3.24-3.34 
(m, 1H, 5´-H), 3.09-3.16 (t, 2H, CH2), 2.51-2.70 (m, 2H, P-O-CH2), 1.08-1.32 (m, 12H, 
4CH3), 0.72-0.77 (d, 9H, (CH3)3), (-0.09)-(-0.04) (d, 3H, CH3), (-0.33)-(-0.28) (d, 3H, 
CH3). 13C NMR (75 MHz, CDCl3): δ 164.5, 158.6, 156.8, 155.9, 152.4, 146.4, 145.0, 
144.9, 137, 136, 134.5, 132.8, 130.4, 129.3, 129, 128.6, 128, 127, 117.6, 113.3, 98.8, 
87.0, 86.5, 83.9, 73, 71.2, 63.5, 59.0-59.4 (d), 55.5, 43.5-43.8 (d), 35.5, 25.8, 24.7-25.2 
(m), 21.4, 20.7, 18.2, 14.5, -4.4, -5.0. 31P NMR (CD2Cl2): 149.0, 151.4. HRMS: calcd for 
C61H74N7O9NaSiP [MNa+] 1130.4953, obsd 1130.4973.  
          5´,3´-O-Bis(t-butylsilyl)-2´-O-(t-butyldimethylsilyl)-8-cyclohexylethoxyaden-
osine (14). Yield 65%; silica gel TLC Rf  0.49 (2:3 hexane:ethyl acetate); 1H NMR (300 
MHz, CDCl3): δ 8.20 (s, 1H, 2-H), 5.89 (d, 1H, 1´-H), 5.34(s, 2H, NH2), 4.92-4.97 (m, 
1H, 2´-H), 4.68-4.74 (d, 1H, 3´-H), 4.47-4.61 (m, 2H, OCH2), 4.34-4.44 (m, 1H, 4´-H), 
3.98-4.12 (m, 2H, 5´-H), 1.16-1.82 (m, 13H, C6H11CH2), 1.02-1.16 (d, 18H, (CH3)3), 0.89 
(s, 9H, (CH3)3), 0.04-.12 (d, 6H, 2CH3). 13C NMR (75 MHz, CDCl3): δ 154.4, 153.2, 
151.4, 149.6, 116.3, 90.4, 75.4, 74.6-74.8, 67.2, 67.8, 36.4, 33.3, 27.8, 27.3, 26.6, 26.3, 
26.1, 22.9, 20.5, 18.6, -4.3, -4.9. HRMS: calcd for C32H58N5O5Si2 [MH+] 648.3977, obsd 
648.4002.  
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          5´,3´-O-Bis(t-butylsilyl)-2´-O-(t-butyldimethylsilyl)-N6-benzoyl-8-cyclohexylet-
hoxyadenosine (15). Yield 84-92%; silica gel TLC Rf  0.73 (2:3 hexane:ethyl acetate); 1H 
NMR (300 MHz, CDCl3): δ 8.76-8.82 (bs, 1H, CONH-), 8.59 (s, 1H, 2-H), 7.95-8.02 (m, 
2H, PhCO), 7.48-7.62 (m, 3H, PhCO) 5.91-5.95 (d, 1H, 1´-H), 4.88-4.97 (q, 1H, 2´-H), 
4.70-4.75 (d, 1H, 3´-H), 4.53-4.69 (m, 2H, OCH2), 4.35-4.43 (q, 1H, 4´-H), 4.98-4.14 
(m, 2H, 5´-H), 1.16-1.82 (m, 13H, C6H11CH2), 1.13 (s, 9H, (CH3)3), 1.05 (s, 9H, (CH3)3), 
0.89 (s, 9H, (CH3)3), 0.06-0.14, (d, 6H, CH3). 13C NMR (75 MHz, CDCl3): δ 165, 156.1, 
152.1, 150.5, 146, 134.2, 132.7, 129.0, 128.0, 121.0, 90.5, 75.4, 74.8, 70.0, 67.7, 36.3, 
33.3, 27.8, 27.3, 26.6, 26.3, 26.1, 22.9, 20.6, 18.7, -4.1, -5.0. HRMS: C39H61N5O6NaSi2 
[MNa+] 774.4058, obsd 774.4078. 
          2´-O-t-Butyldimethylsilyl-N6-benzoyl-8-cyclohexylethoxyadenosine(16). Yield 
87-90%; silica gel TLC Rf  0.16 (2:3 hexane:ethyl acetate); 1H NMR (300 MHz, CDCl3): 
δ 8.79 (s, 1H, CONH-), 8.64 (s, 1H, 2-H), 7.94-8.00 (m, 2H, PhCO), 7.47-7.60 (m, 3H, 
PhCO), 6.04-6.12 (d, 1H, 5´-OH), 5.88-5.92 (d, 1H, 1´-H), 5.08-5.16 (q, 1H, 2´-H), 4.48-
4.64 (m, 2H, OCH2), 4.30-4.36 (m, 2H, 3´-H and 4´-H), 3.88-3.98 (d, 1H, 5´-H), 3.67-
3.78 (t, 1H, 5´-H), 2.90 (s, 1H, 3´-OH), 0.9-1.80 (m, 13H, C6H11CH2), 0.80 (s, 9H, 
(CH3)3), -0.14 (s, 3H, CH3), -0.37 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3): δ 164.7, 
156.6, 151.0, 150.4, 147.0, 134.3, 132.9, 129.0, 127.0, 120.9, 88.0, 87.4, 73.9, 73.0, 70.2, 
63.7, 36.3, 34.5, 33.4, 26.6, 26.3, 25.7, 18.0, -5.0, -5.2. HRMS: calcd for C31H46N5O6Si 
[MH+] 612.3217, obsd 612.3228.   
          5´-O-(4,4´-Dimethoxytrityl)-2´-O-(t-butyldimethylsilyl)-N6-benzoyl-8-cyclohex-
ylethoxyadenosine (17). Yield 74-78%; silica gel TLC Rf  0.59 (2:3 hexane:ethyl 
acetate); 1H NMR (300 MHz, CDCl3): δ 8.70 (s, 1H, CONH-), 8.46 (s, 1H, 2-H), 7.96-
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8.02 (m, 2H, PhCO), 7.14-7.62 (m, 12H, Ph), 6.72-6.80 (dd, 4H, Ph), 5.88-5.93 (d, 1H, 
1´-H), 5.33-5.39 (t, 1H, 2´-H), 4.53-4.62 (t, 2H, OCH2), 4.38-4.44 (q, 1H, 3´-H), 4.16-
4.23 (q, 1H, 4´-H), 3.76 (s, 6H, OCH3), 3.30-3.50 (m, 2H, 5´-H), 2.73-2.77 (d, 1H, 3´-
OH), 0.92-1.80 (m, 13H, C6H11CH2), 0.84 (s, 9H, (CH3)3), -0.02 (s, 3H, CH3), -0.2 (s, 3H, 
CH3). 13C NMR (75 MHz, CDCl3): δ 164.8, 158.6, 156.8, 152.0, 150.8, 146.3, 145.0, 
136.3, 136.2, 134.5, 132.7, 130-130.4 (d), 129.1, 128.5, 127.9, 126.9, 120.5, 113.2, 87.3, 
86.4, 84.1, 72.7, 71.7, 70.0, 63.9, 55.4, 36.3, 34.5, 33.4, 33.3, 26.8, 26.4, 25.8, 18.1, -4.7, 
-4.8 HRMS: calcd for C52H63N5O8NaSi [MNa+] 936.4344, obsd 936.4332. 
          5´-O-(4,4´-Dimethoxytrityl)-3´-O-[(2-cyanoethoxy)(N,N-diisopropylamino)ph-
osphino]-2´-O-(t-butyldimethylsilyl)-N6-benzoyl-8-cyclohexylethoxyadenosine (18). 
Yield 78-85%; silica gel TLC Rf  0.59 (2:3 hexane:ethyl acetate); 1H NMR (300 MHz, 
CDCl3): 8.64-8.72 (d, 1H, CONH-), 8.35-8.44 (t, 1H, 2-H), 7.96-8.02 (m, 2H, PhCO), 
7.16-7.62 (m, 12H, Ph), 6.74-6.82 (m, 4H, Ph), 5.86-5.94 (t, 1H, 1´-H), 5.35-5.48 (m, 1H, 
2´-H), 4.53-4.62 (t, 2H, OCH2), 4.44-4.53 (m, 1H, 3´-H), 4.24-4.40 (m, 1H, 4´-H), 3.88-
4.0 (m, 1H, 5´-H), 3.77 (s, 6H, OCH3), 3.51-3.70 (m, 4H, CH2CN, 2CHN), 3.24-3.38 (m, 
1H, 5´-H), 2.54-2.74 (m, 2H, P-O-CH2), 0.84-1.80 (m, 13H, C6H11CH2; m, 12H, 4CH3), 
0.72-0.80 (d, 9H, (CH3)3), (-0.08)-(-0.04) (t, 3H, CH3), (-0.30)-(-0.26) (d, 3H, CH3). 13C 
NMR (75 MHz, CDCl3): δ 164.8, 158.6, 150.7, 145.0, 136.2, 132.8, 130.4, 129.1, 128.5, 
128.0, 127.0, 120.1, 113.2, 86.4-87.0 (q), 83.0, 70.0, 63.8, 59.0, 59.4, 55.3, 53.5, 43-43.4 
(d), 36.3, 34.5, 33.2, 33.4, 26.6, 26.4, 25.8, 24.6-25.1 (m), 20.5-20.8, 18.1, -4.3, -4.9. 31P 
NMR (CD2Cl2): 148.9, 151.5. HRMS: calcd for C61H80N7O9NaSiP [MNa+] 1136.5422, 
obsd 1136.5436. 
	   68	  
          Design of the caspase 2 siRNA and synthesis of the modified guide strands.   
Caspase 2 siRNA (A:U) and the corresponding negative control siRNA (scrambled 
sequence) was designed using Ambion’s siRNA designing tool and checked for sequence 
similarity using nucleotide Basic Local Alignment Search Tool (BLAST). No significant 
similarity was found with other genes. To analyze caspase 2 expression levels quickly 
and reliably, a plasmid-based dual luciferase assay system (psiCHECK2 vector) was 
employed.  A fragment of the caspase 2 mRNA sequence was inserted into the vector, 
and the resulting reporter plasmid was used to evaluate caspase 2 mRNA knockdown.  
          8-AlkoxyA phosphoramidites was subsequently coupled into various positions of 
the guide strand of the caspase 2 siRNA. All siRNA oligonucleotides, modified and 
unmodified, were synthesized by standard solid-phase RNA synthesis on DNA columns 
in the DNA/Peptide Core Facility of the University of Utah using an Applied Biosystems 
(Model 394) DNA/RNA synthesizer. The positions chosen for single substitution were 4, 
6, 10 and 15; doubly modified guide strands had modifications at (6,10), (6,15) and (10, 
15) positions (Figure 2.10).  
          Synthesis and purification of siRNAs. After synthesis, the 21-mer RNA 
oligonucleotides were cleaved from the column and deprotected using methanolic 
ammonia for 24 h at room temperature, and the 2´-OTBDMS group was deprotected by 
using TEA•3HF overnight at room temperature. The oligomers were then dialyzed at 4 
°C for 6 h, purified by semi-preparative ion-exchange HPLC, dialyzed at 4 °C again to 
get rid of excess salt, lyophilized and stored at -20 °C under dry conditions.      
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Figure 2.10.  SiRNA sequences used. A:U represents unmodified siRNA and modified 
(denoted by M:G) sequences have the standard A:U base pair replaced by 8-

































M =  8-PgOA (8-propargyloxyA)                
        8-PeOA (8-phenylethoxyA)                
        8-CeOA (8-cyclohexylethoxyA )
M4 = Guide strand containing M at position 
4 from the 5'-end of the strand
R
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          ESI-MS characterization of the modified guide strands. Two nanomoles of each 
modified guide strands were extensively dialyzed for 2 days at 4 °C in ammonium acetate 
solution to get rid of excess sodium ions. The final dialysis was carried out in water. The 
oligomers were then lyophilized, and dissolved in 1:1 isopropanol:water and analyzed by 
electrospray ionization mass spectrometry (ESI-MS) in negative ion mode. The results 
are furnished in the Table 2.1. 
 
Results and discussion 
          Purines can exist preferentially as the anti conformer and participate in canonical 
Watson-Crick H-bonding with their complementary bases. However, there is evidence of 
transient syn adenosines in duplex RNA (24). Also, in the context of AG mismatches, 
there is evidence of syn A in double-stranded DNA (25). It was observed that the syn/anti 
equilibrium of purines could be shifted more towards the syn conformation by 
introducing a substitution at position 8; this substituent experiences a steric clash with the 
5´ hydrogen atoms of the ribose backbone as well as with the 4´ oxygen, facilitating the 
syn conformation to a greater extent than the unmodified purine. 
          Indeed, 8-BrdG, 8-O-dA, 8-O-dG, 8-BrdA and 8-MeOdA are known to exist in 
mixtures of syn/anti equilibrium (26-29). Here, the unusual RNA base modification 8-
alkoxyA was chosen as a potential ‘conformational switch’ in the guide strand of a 
caspase 2 siRNA. 8-AlkoxyA, being a Janus-faced base, can expose the Watson-Crick 
face in the anti conformation, as well as the Hoogsteen face in the syn conformation; thus 
anti 8-alkoxyA can base-pair canonically with U and syn 8-alkoxyA has potential to form 
H-bonds with anti G (Figure 2.6). 
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Table 2.1. ESI-MS of the modified guide strands. 
 
 
Guide strand  
 
Guide strand sequences Calculated mass Experimental mass 
Pg4 
 
3´- ttGGGAAGACGAAAGAUPgAUG - 5´ 6897.4 6896.9 
Pg6 
 
3´- ttGGGAAGACGAAAGPgUAAUG - 5´ 6897.4 6896.8 
Pg10 
 
3´- ttGGGAAGACGPgAAGAUAAUG - 5´ 6897.4 6896.9 
Pg15 
 
3´- ttGGGAPgGACGAAAGAUAAUG - 5´ 6897.4 6896.9 
Pg6,10 
 
3´- ttGGGAAGACGPgAAGPgUAAUG - 5´ 6973.4 (Na+ salt) 6972.5 
Pg6,15 
 
3´- ttGGGAPgGACGAAAGPgUAAUG- 5´ 6973.4 (Na+ salt) 6972.8 
Pg10,15 
 
3´- ttGGGAPgGACGPgAAGAUAAUG - 5´ 6973.4 (Na+ salt) 6972.8 
Pe4 
 
3´- ttGGGAAGACGAAAGAUPeAUG - 5´ 6963.6 6964.8 
Pe6 
 
3´- ttGGGAAGACGAAAGPeUAAUG - 5´ 6963.6 6964.8 
Pe10 
 
3´- ttGGGAAGACGPeAAGAUAAUG - 5´ 6963.6 6964.0 
Pe15 
 
3´- ttGGGAPeGACGAAAGAUAAUG - 5´ 6963.6 6964.8 
Pe6,10 
 
3´- ttGGGAAGACGPeAAGPeUAAUG - 5´ 7083.8 7083.6 
Pe6,15 
 
3´- ttGGGAPeGACGAAAGPeUAAUG - 5´ 7083.8 7083.7 
Pe10,15 
 
3´- ttGGGAPeGACGPeAAGAUAAUG - 5´ 7083.8 7083.1 
Ce4 
 
3´- ttGGGAAGACGAAAGAUCeAUG - 5´ 6969.6 6969.6 
Ce6 
 
3´- ttGGGAAGACGAAAGCeUAAUG - 5´ 6969.6 6969.6 
Ce10 
 
3´- ttGGGAAGACGCeAAGAUAAUG - 5´ 6969.6 6970.4 
Ce15 
 
3´- ttGGGACeGACGAAAGAUAAUG - 5´ 6969.6 6970.4 
Ce6,10 
 
3´- ttGGGAAGACGCeAAGCeUAAUG - 5´ 7095.8 7095.5 
Ce6,15 
 
3´- ttGGGACeGACGAAAGCeUAAUG - 5´ 7095.8 7095.0 
Ce10,15 
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          8-AlkoxyA phosphoramidites were synthesized in good yields in multiple steps 
from A. 8-AlkoxyA was synthesized from the corresponding bromo intermediate through 
aromatic nucleophilic substitution of the Br group with the alkoxy group. The initial 
bromination of adenosine is a literature procedure. Usually, three- to four-fold excess of 
bromine afforded good yields (75-82.5%) of the 8-bromoadenosine (1).  
          A major problem in the standard synthesis of ribo-phosphoramidites is the selective 
protection of the 2´-OH group over the 3´-OH. The Ag+ ion was reported to improve the 
yield of the 2´-O-protected intermediate; but even Ag+ ion cannot always minimize the 
unavoidable reaction at the 3´-OH (30). As a consequence, the overall yield of the desired 
phosphoramidite is significantly reduced. To accomplish a better overall yield, we 
decided to use a bidentate hydroxyl protecting group, di-t-butylsilyl ditriflate (DTBSDT) 
(23), that will protect the 5´- and 3´-OH simultaneously, leaving the 2´-OH ready to be 
protected by t-butyldimethylsilyl group. These consecutive steps were basically a one-pot 
reaction; so no tedious separation was required. Additionally, the reaction was almost 
quantitative with 98% product (3) yield.  
          Synthesis of the propargyloxy derivative (4) was accomplished by the in-situ-
generated 8-propargyloxylithium reagent; the reagent was synthesized by the reaction of 
n-BuLi with excess anhydrous propargyl alcohol in THF. This reaction was also very 
efficient and the yield was 94%. In spite of using such a harsh condition, no detectable 
side reaction was observed.  
          The exocyclic NH2 of 4 was protected using the benzoyl group. When benzoyl 
chloride was used as the benzoylation reagent in pyridine, dibenzoyl derivative is also 
formed. Brief ammonia (in methanol) treatment was necessary to convert the dibenzoyl 
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derivative to the monobenzoyl one. Selective deproection of the 5´- and 3´-hydroxyls was 
carried out by using a mild fluoride reagent, HF-pyridine. However, at 25 °C both the 
DTBSDT and the TBDMS protecting groups are deprotected (23), By carrying out the 
reaction at –10 °C for 2-2.5 h, 2´-OTBDMS protection remains intact.  
          Following standard solid phase oligonucleotide synthesis, the 5´-OH was protected 
by the DMT group. Literature yields of this reaction for many modified nucleosides are 
always low to moderate. In this case the yield was low (<50%) initially; however 
changing the reaction conditions slightly afforded 70-80% yields. Addition of DMT-Cl to 
the solution (in pyridine) of 6 at low temperature (0 °C) and gradually warming up the 
solution was essential to obtain higher yields. Addition of one more equivalent of DMT-
Cl after 8 h of the first addition also improved yield of the DMT derivative. The 
propargyloxy phosphoramidite (7) was synthesized in good yield using standard 
phosphoramidite reagent. The phosphoramidite is stable for 48 h in methylene chloride or 
THF; if lyophilized, it can be stored at -20 °C for a year without degradation. 
          The 8-benzyloxy derivative, synthesized from 3, was partially degraded during 
chromatographic separation (slightly acidic pH) of the nucleoside analog (Figure 2.11). 
We were doubtful whether this modification could survive through the strongly acidic 
solid phase synthetic steps and the RNA deprotection steps. Hence we decided to explore 
the phenylethoxy and cyclohexylethoxy modifications in this context. Phosphoramidites 
containing these two modifications were synthesized following analogous procedures. 
Coupling efficiency of the modified phosphoramidites were slightly inferior to natural 
ribonucleoside phosphoramidites probably due to the presence of sterically demanding 
alkoxy groups at position 8 of the adenine ring. 
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Mass spectral analysis of the 8-alkoxyadenosine containing, guide strands confirmed 
their solid phase incorporation into oligoribonucleotides and stability under normal RNA 
deprotection conditions (Table 2.1). However, these modified nucleosides start degrading 
at high pH (>8.5); under this condition, the alkoxy group is converted to oxo group, 
probably through an aromatic nucleophilic substitution mechanism. Hydroxide anion 
substitutes the alkoxy group and the resultant 8-hydroxyA tautomerizes to the more stable 
8-oxoA.  
          Modifications were placed in the guide strand because, not too many successful 
base modifications were known, to date, in the guide strand (21, 31). Also guide base 
modifications can interact with the RNAi machinery even when the passenger strand is 
stripped of the RISC complex; hence intricate mechanistic details can be explored with 
appropriate modifications. This is certainly not possible with the passenger strand 
modifications.   
          Propargyl, phenethyl and cyclohexylethyl groups were chosen based on the size 
and shape of the alkyl groups.  The choice of alkyl groups was also considered in terms 
of prevention of siRNA-PKR interaction as well as maintenance of target mRNA 
knockdown. Methyl or ethyl groups might be too small to have any significant impact on 
the siRNA-protein interactions. However, it was also anticipated that too large a group in 
the guide strand might reduce significantly or even completely abolish the RNAi 
efficacy.      
          Hence, we explored the series with the propargyloxy modification, which was 
expected to retain the RNAi efficacy, as well as prohibit the unwanted protein binding to 
some extent.  The phenylethoxy group was chosen as the most promising group in the 
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guide strand, which could serve both purposes.  We were optimistic that cyclohexylethyl 
modifications will prevent dsRBM-containing proteins from binding siRNAs, but were 
interested to explore whether such a large modification might also compromise RNAi 
efficacy. 
          Earlier, Beal and coworkers reported that minor-groove base modifications in the 
passenger strand could prevent PKR and ADAR1 binding when modifications were 
placed at 6, 9, 11 and 14 or at proximate positions (Figure 2.8) (18). 8-AlkoxyA was 
substituted for A in single or multiple positions of the guide strands; so, the presence of 
an A in those positions or at nearby positions was taken into account while making the 
selection. 
          Positions of modifications were based on significance of the positions for 
mediating the gene silencing, as well as preventing the off-pathway protein binding. 
Positions 4 and 6 (from the 5´-end of the guide strand) are important positions in the seed 
region of siRNA; position 10 is just next to the cleavage site. We were interested to know 
the effect of moderate (propargyloxy) or large (phenylethoxy and cyclohexylethoxy) 
modifications in the minor and major grooves at these sites. Position 15 is located 
towards the 3´-terminal of the guide strand and this part of the siRNA is known to 




          Chemical modifications impart many novel properties into siRNAs that are not 
achievable in unmodified siRNAs. Ribose modifications such as UNA helped reduce off-
target effects and prevented sequence-dependent off-target effects. 2´-F Modifications 
helped achieve target specificity. Off-pathway protein interactions with the siRNA are 
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still one of the major limitations of the siRNA-based RNAi therapeutics. These undesired 
interactions reduce the effective concentration of the siRNA in vivo, instigate interferon-
mediated immunostimulation, and globally affect the expression of many unrelated 
genes.  Therefore, these interactions need to be successfully prevented to maximize the 
therapeutic efficacy of the siRNA.  
          The Beal laboratory and the Burrows laboratory are systematically exploring the 
possibilities of nucleobase modifications to address off-pathway protein binding with the 
siRNA. Minor grove modifications of purines, e.g., guanine and 2-aminopurine, in the 
passenger strand of a caspase 2 siRNA blocked such off-pathway interactions.  Kannan et 
al. reported ‘switchable’ N2 alkylated 2´-deoxy-7,8-dihydro-8-oxoguanosine in the guide 
strand of an siRNA to reduce the siRNA-PKR interaction, while not compromising the 
RNAi efficacy by much. However, 2´-deoxy-7,8-dihydro-8-oxoguanosine lesions are 
known to be immunostimulatory; therefore development of alternative base ‘switches’ is 
essential for effective substitution in the guide strand.    
          8-Substituted adenosines are known to exist in a mixture of syn and anti 
conformation around the glycosidic bond and can function as Janus-faced bases. Thus 8-
alkoxyA can also exist as syn or anti conformer depending on the base-pairing partner. In 
the syn conformation, 8-alkoxyA can expose its Hoogsteen face to the complementary 
base and hence can base-pair with anti G; on the other hand, anti 8-alkoxyA can utilize 
its natural Watson-Crick face to form hydrogen bonding with anti U. These ‘switchable’ 
bases have the potential to prevent off-pathway interaction with dsRBM containing 
proteins in the syn conformation, as well as maintain RNAi efficacy as the anti 
conformer.           
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          In this study, 8-alkoxyA phosphoramidites were synthesized and incorporated into 
the guide strand of a caspase 2 siRNA.  Three different alkyl groups were used for the 
alkoxy modifications: propargyl (Pg), phenethyl (Pe) and cyclohexylethyl (Ce). Yields 
were good for both 8-propargyloxyA (8-PgOA) and 8-phenylethoxyA (8-PeOA) 
phosphoramidites; however the 8-cyclohexylethoxyA (8-CeOA) derivative afforded 
moderate yield. Modified phosphoramidites were incorporated into the guide strand of a 
caspase 2 siRNA through the solid phase oligonucleotide synthesis. Four singly modified 
and three doubly modified guide strands were synthesized to explore the effect of 
modifications on RNAi efficacy and off-pathway protein binding.  Modified siRNA 
strands were stable under normal RNA deprotection conditions. ESI-MS analysis of the 
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THERMAL ANALYSIS AND BIOLOGICAL EVALUATION  
 
  OF THE MODIFIED SIRNAS  
 
Introduction 
          Thermal denaturation studies of duplex nucleic acid oligomers is important in 
many biological applications such as in qualitative and quantitative PCR, hybridization 
probes, sequencing, aptamer and ribozyme designing and in the antisense and RNAi 
technologies. If the thermal stability of a duplex nucleic acid is very high, it will not 
unwind easily and the desired functions of the oligonucleotide will be affected; 
contrarily, instability of the duplex will pose similar problems. In addition, poor thermal 
stability will decrease the solution and nuclease stability of RNAs, because RNA is many 
times more stable as a duplex than as single strands.  
          The melting temperature (Tm) of a duplex oligonucleotide is defined as the 
temperature at which 50% of the duplexes exist as single strands. This dual state model 
holds good for most short oligonucleotides, but for long oligonucleotides complex 
transition patterns might be observed.  
          Importance of thermal denaturation analysis of the siRNA. Thermal analysis of 
the siRNA is a crucial step in designing potent and specific RNAi therapeutics. For 
effective gene silencing through RNAi, optimal melting temperature of the siRNA is 
desired. Many factors can influence the Tm of an siRNA; some important parameters are 
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the sequence, siRNA concentration and salt concentration. Generally GC-rich sequences 
have higher Tm compared to AT-rich sequences; for optimal RNAi efficacy of the 
siRNA, 38-60% GC content is desirable. The Tm of an siRNA is also dependent on the 
nucleotide and salt concentration in the solution; the higher the concentration, the higher 
is the Tm. Hydrogen bonding interactions between the complementary bases and base 
stacking interactions from the nearest neighbors play crucial roles in determining the Tm 
of an siRNA. 
          Higher thermal stability of the siRNA duplex at the 3´-end of the guide strand 
compared with the 5´-end is desired for optimal RNAi efficacy. Therefore, many 
successful siRNAs have a GC-rich region towards the 3´-end of the guide strand.  
          Consequences of different chemical modifications on the melting temperature 
(Tm) of the siRNAs. Chemically modified siRNAs are now integral parts of the siRNA 
therapeutics; therefore, the effect of any modification on the thermal stability of the 
duplex is an important consideration as well. Backbone modifications have mixed effects 
on the thermal stability of the siRNA. Phosphorothioate (PS) (1) modifications slightly 
lower the Tm of an siRNA, whereas boranophosphate (BP) (2, 3) modifications elevate 
this parameter slightly. Small ribose modifications may elevate the Tm of the siRNA (1, 
4); contrarily, large ones destabilize it and the extent of destabilization depends on the 
size of the substituted group (5). 2´-Deoxy modifications lower the Tm of the siRNAs 
slightly, and substitution of the 4´-O with S has enhanced the Tm. Locked nucleic acids, 
LNA and ENA (1) and 2´-F (4) modifications increases the Tm of the duplex by helping 
the modified nucleoside to attain  the RNA-like ‘3´-endo’ conformation. 
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          Base modifications bring about the greatest changes in the thermal stability of the 
siRNA. Modifications that disrupt hydrogen bonding between bases (e.g. in N3-Me-U), 
drastically lower the thermal stability of the duplex, whereas those enhancing base 
pairing strength through additional hydrogen bond(s) (2,6-diaminopurine) increase the Tm 
(6). Placement of hydrophobic nucleoside mimetics in the siRNA, lower the thermal 
stability of the duplex (7, 8). The Kool group reported siRNA major groove 
modifications that can stabilize the duplex RNA more than the unmodified ones (9). RNA 
minor groove modifications have always lowered the Tm irrespective of the position and 
size of the modification and the nature of the base modified (10-12). 
          Influence of thermal stability on the RNAi efficacy. An siRNA needs to be 
sufficiently stable as a duplex to be able to knock down a specific mRNA; however no 
general trend was observed between the Tm of the siRNA and the RNAi efficacy. Rana 
and coworkers reported that strengthening the hydrogen bonding, thereby elevating the 
Tm of the siRNA, between the complementary nucleobases has a deleterious effect on the 
RNAi efficacy. Thus 2,6-diaminopurine, when used in place of A towards the 5´-end of 
the guide strand, makes the siRNA less effective (6). Their study implies that the thermal 
asymmetry of the siRNA is more important than its thermal stability; the 5´-end of the 
guide strand should always be less stable than the 3´-end.  
          This observation was further clarified by utilizing hydrophobic and non-hydrogen-
bonding nucleobase isosteres in the seed region of the passenger strand of an siRNA. 
Modifications such as 2,4-difluorotoluene, hypoxanthine, 5-nitroindole, purine, and 2-
aminopurine at various positions within the passenger strand, improved RNAi efficacy 
mainly due to thermal destabilization (by 1 to 12 °C) of the duplex (13). On the contrary, 
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ribose modifications, such as LNA, ENA (1) and 2´-F (4) substitutions, substantially 
raised the Tm without compromising the RNAi efficacy.  
         Chemical modifications modulate siRNA efficacy. Chemical modifications of the 
ribose moiety (1, 4, 6, 14-28) and the phosphodiester backbone (1, 6, 18) have improved 
siRNA stability (1, 4), ribonuclease resistance (1, 14, 17, 19, 22), potency (14, 19, 27) 
and specificity (1, 29). Numerous polymer- (30-32), lipid- (33), cholesterol- (34, 35), 
carbohydrate- (30, 31), peptide- (36) and small molecule-based (34) terminal 
modifications of the siRNA exhibited effective RNA interference and polymer- and 
cholesterol-based conjugates facilitated intracellular delivery of siRNA both in vitro and 
in vivo (37). Base modifications have been shown to enhance thermal stability (9) and 
nuclease stability (7); these also helped visualize intracellular trafficking (38) and 
reduced off-target effects (10, 11, 39). Recently, major groove substitution of modified 
purines in various positions of the guide strand have been reported; here also RNAi 
efficacy was found to be position dependent (40). 
          Off-pathway protein interactions with the siRNA. Along with the targeted 
delivery issue, off-target gene silencing and off-pathway protein interactions leading to 
immunostimulation are still the major limitations for rapid optimization of the siRNA 
therapeutics. Specific siRNA sequences can bind to toll-like receptors and lead to 
immunostimulation (41-45). In addition, sequence-independent off-pathway protein 
interactions involve binding of virtually any siRNA with double-stranded RNA binding 
motif (dsRBM) containing proteins, e.g., RNA-dependent protein kinase (PKR), 
adenosine deaminases (ADARs) and other intracellular proteins (46, 47). PKR activation 
leads to phosphorylation of eukaryotic Initiation factor 2, inhibition of translation 
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initiation and other antiviral signaling events (48). Although siRNAs are shorter than 
ligands that trigger high PKR activity, lower level activation of PKR has been observed 
with siRNAs in vitro and when transfected into certain cell types (41).   
ADARs also bind dsRNA and have been shown to interact with substrates within 
the RNAi pathway (49, 50). The full-length isoform of ADAR1 (ADAR1p150) has been 
linked to decreased siRNA potency in mammalian cells, presumably due to the formation 
of high affinity siRNA•ADAR1p150 complexes within the cytoplasm (51). Additionally, 
ADAR has been shown to reduce RNAi efficiency in Drosophila cell culture (50). 
Therefore, prevention of the siRNA binding to dsRBM-containing proteins off the RNAi 
pathway is important for the potency and specificity of therapeutic RNAi.   
Some nucleoside analogs have shown promise in preventing PKR binding, but no 
systematic study with modified sugars to address such sequence-independent induction of 
immunostimulation is available (52). On the other hand, altering the RNA minor groove 
through base modifications has shown potential in modulating siRNA properties and 
siRNA-protein interactions.  The Beal laboratory initiated a systematic study on siRNA 
base modifications that could block off-pathway protein binding (53), and they have also 
shown that pendent minor groove modifications of guanines (10) and 2-aminopurines 
(11) in the passenger caspase 2 siRNA can successfully prevent siRNA-dsRBM 
interactions, while maintaining the RNAi efficacy.  
          Guide strand nucleobase modifications to prevent off-pathway protein 
binding. Base modifications in the guide strand are more challenging, since many 
modifications at crucial siRNA sites (e.g., in the seed region or at the cleavage site) will 
drastically reduce the silencing efficacy or might even completely abolish the knockdown 
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of the desired mRNA. In contrast, modifications at those sites might, in fact, turn out to 
be more exciting and lead to elucidation of crucial mechanisms in the RISC complex. For 
example, appropriate modifications in the minor or major groove of an siRNA can help 
explore the siRNA mechanisms in detail, and placement of designer modifications in 
those grooves can provide further novel insights into the siRNA-RISC interactions.  
          Kannan et al. have shown that N2-alkylated 2´-deoxy-7,8-dihydro-8-oxoguanosine-
containing siRNAs can prevent siRNA-PKR interaction significantly by placing a 
‘switchable’ alkyl group in the minor groove of an siRNA during delivery; in the RISC, 
the modified siRNAs can flip the sterically encumbering group into the major groove and 
maintain good RNAi efficacy (39). However 8-oxoguanine-containing DNA oligomers 
are known to be inflammatory and immunostimulatory themselves (54, 55). Therefore, 
we chose to explore alternative purine modifications in the guide strand.  Here we report 
the syntheses, thermal stability and biological activity of 8-alkoxyA-substituted siRNAs. 
          Janus-faced 8-alkoxyA nucleosides in the guide strand. 8-AlkoxyA-modified 
siRNAs were tested for their RNAi efficacy and ability to address off-pathway protein 
binding due to siRNA-PKR interactions. 8-Substituted adenosines and guanosines have 
been shown to exist in an equilibrium mixture of syn/anti conformers.  In this work, 8-
alkoxyAs are postulated to flip between anti and syn conformations depending on the 
base-pairing partner.  In the natural anti conformation, 8-alkoxyA will base pair with U; 
whereas in the syn conformation, the Hoogsteen face of the nucleoside will be exposed 
for base pairing, and its best complement would be anti G (Figure 3.1).  We propose that, 
during siRNA delivery, 8-alkoxyA in the guide strand (complementary to G in the 
passenger strand) would project the bulky alkoxy group into the minor groove of siRNA,  







Figure 3.1. Proposed 8-AlkoxyA ‘base switches’. (A) Cartoon showing flipping of a 
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thereby preventing off-pathway protein binding. When the siRNA is recruited into the 
RISC assembly, the 8-alkoxyA in the guide siRNA would encounter U in the mRNA and 
would flip the bulky appendage into the major groove, thereby allowing necessary guide 
strand-mRNA-RISC assembly to form.    
          Alkyl groups chosen based on size and shape are propargyl (Pg), phenethyl (Pe) 
and cyclohexylethyl (Ce).  The rationale behind the choices is that smaller groups (such 
as propargyl) might exhibit higher duplex stabilities and better mRNA knock 
downefficiencies whereas a larger group (cyclohexylethyl) might prevent 
immunostimulation to a greater extent, and a medium sized group (phenethyl) might 
serve both the purposes equally efficiently.   
Our study suggests that the mRNA knock down ability of the singly modified 
siRNAs is quite similar to that of the unmodified positive control siRNA.  Singly 
modified siRNA oligomers have also exhibited a reduced tendency to bind PKR. With 
additional alkoxy substitution, the efficiency of the siRNA is significantly reduced; 
therefore multiply modified siRNAs were not tested for off-pathway protein interactions.  
 
Experimental 
          SiRNA annealing. SiRNA oligomers were dissolved in annealing buffer (100 mM 
NaCl and 10 mM TRIS, pH 7.1), and appropriate guide and passenger strands were 
mixed in equal amounts in an Eppendorf tube. The nucleotide mixtures were placed in a 
90 °C water bath for 5 min, and the bath was gradually cooled to room temperature in 
about 2 h.  
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          Thermal analysis of the modified siRNAs. Modified guide strands were 
hybridized against passenger strands containing both U and G (Tables 3.1 and 3.2). 
Melting temperature experiments of the hybridized duplexes were performed in a 
Beckman DU 650 spectrophotometer. In all experiments, the temperature was varied 
from 25 °C to 80 °C, and the rate of heating was 0.5 °C/min. Thermal denaturation was 
monitored at 260 nm. All experiments were performed with 1 nmol duplex RNA in 
siRNA annealing buffer (containing 10mM Tris, 100 mM NaCl, pH 7.1) in triplicate and 
normalized to appropriate blank controls. The reported Tm value was the average of 3 
independent experiments, and error bars represent standard deviation from the average 
value. Experimental data were analyzed by ‘two point average’ method. 4 cuvettes were 
filled with 325 µL annealing buffer and were read as blanks. Then, 3 cuvettes were 
emptied, and 1 nmol siRNA duplex was added to the siRNA annealing buffer so that the 
total volume of the mixture became 975 µL. This mixture was equally distributed in those 
3 cuvettes, and the fourth cuvette was loaded with 325 µL annealing buffer. Lids were 
closed tightly and temperature was varied from 25 to 80 °C.     
          Synthesis of the wild-type and mutant plasmids. The appropriate caspase 2 
inserts (Figure 3.3) were introduced into the psiCHECK2 vector (Figure 3.2) using the 
multiple cloning region of the plasmid. One wild type and two mutant plasmids were 
synthesized. The plasmids were multiplied in E. coli, extracted by Qiagen mini plasmid 
extraction kit and sequenced at the Core Facility, University of Utah. Figure 3.4 furnishes 
a brief protocol for the synthesis of the recombinant plasmid. 
          Cell culture. HeLa cells were cultured in Dubelco’s DMEM cell culture medium 
with 10% FBS and maintained under 5% CO2 in an incubator. Corning 75 mL and 225  
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Table 3.1. Caspase 2 siRNAs containing 8-alkoxyA in the guide strands and U in the 
complementary passenger strands.  
 
 
SiRNA  Guide strand sequences Passenger strand sequences 
A:U 5´-GUAAUAGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pg4:U 5´-GUAPgUAGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pg6:U 5´-GUAAUPgGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pg10:U 5´-GUAAUAGAAPgGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pg15:U 5´-GUAAUAGAAAGCAGPgAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pg6,10:U 5´-GUAAUPgGAAPgGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pg6,15:U 5´-GUAAUPgGAAAGCAGPgAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pg10,15:U 5´-GUAAUAGAAPgGCAGPgAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pe4:U 5´-GUAPeUAGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pe6:U 5´-GUAAUPeGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pe10:U 5´-GUAAUAGAAPeGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pe15:U 5´-GUAAUAGAAAGCAGPeAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pe6,10:U 5´-GUAAUPeGAAPeGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pe6,15:U 5´-GUAAUPeGAAAGCAGPeAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pe10,15:U 5´-GUAAUAGAAPeGCAGPeAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Ce4:U 5´-GUACeUAGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Ce6:U 5´-GUAAUCeGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Ce10:U 5´-GUAAUAGAACeGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Ce15:U 5´-GUAAUAGAAAGCAGCeAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Ce6,10:U 5´-GUAAUCeGAACeGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Ce6,15:U 5´-GUAAUCeGAAAGCAGCeAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Ce10,15:U 5´-GUAAUAGAACeGCAGCeAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
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Table 3.2. Caspase 2 siRNAs containing 8-alkoxyA in the guide strands and G in the 
complementary passenger strands. 
 
 
SiRNA  Guide strand sequences Passenger strand sequences 
A:U 5´-GUAAUAGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAUUACtt-3´ 
Pg4:G 5´-GUAPgUAGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAGUACtt-3´ 
Pg6:G 5´-GUAAUPgGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCGAUUACtt-3´ 
Pg10:G 5´-GUAAUAGAAPgGCAGAAGGGtt-3´ 5´-CCCUUCUGCGUUCUAUUACtt-3´ 
Pg15:G 5´-GUAAUAGAAAGCAGPgAGGGtt-3´ 5´-CCCUGCUGCUUUCUAUUACtt-3´ 
Pg6,10:G 5´-GUAAUPgGAAPgGCAGAAGGGtt-3´ 5´-CCCUUCUGCGUUCGAUUACtt-3´ 
Pg6,15:G 5´-GUAAUPgGAAAGCAGPgAGGGtt-3´ 5´-CCCUGCUGCUUUCGAUUACtt-3´ 
Pg10,15:G 5´-GUAAUAGAAPgGCAGPgAGGGtt-3´ 5´-CCCUGCUGCGUUCUAUUACtt-3´ 
Pe4:G 5´-GUAPeUAGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAGUACtt-3´ 
Pe6:G 5´-GUAAUPeGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCGAUUACtt-3´ 
Pe10:G 5´-GUAAUAGAAPeGCAGAAGGGtt-3´ 5´-CCCUUCUGCGUUCUAUUACtt-3´ 
Pe15:G 5´-GUAAUAGAAAGCAGPeAGGGtt-3´ 5´-CCCUGCUGCUUUCUAUUACtt-3´ 
Pe6,10:G 5´-GUAAUPeGAAPeGCAGAAGGGtt-3´ 5´-CCCUUCUGCGUUCGAUUACtt-3´ 
Pe6,15:G 5´-GUAAUPeGAAAGCAGPeAGGGtt-3´ 5´-CCCUGCUGCUUUCGAUUACtt-3´ 
Pe10,15:G 5´-GUAAUAGAAPeGCAGPeAGGGtt-3´ 5´-CCCUGCUGCGUUCUAUUACtt-3´ 
Ce4:G 5´-GUACeUAGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCUAGUACtt-3´ 
Ce6:G 5´-GUAAUCeGAAAGCAGAAGGGtt-3´ 5´-CCCUUCUGCUUUCGAUUACtt-3´ 
Ce10:G 5´-GUAAUAGAACeGCAGAAGGGtt-3´ 5´-CCCUUCUGCGUUCUAUUACtt-3´ 
Ce15:G 5´-GUAAUAGAAAGCAGCeAGGGtt-3´ 5´-CCCUGCUGCUUUCUAUUACtt-3´ 
Ce6,10:G 5´-GUAAUCeGAACeGCAGAAGGGtt-3´ 5´-CCCUUCUGCGUUCGAUUACtt-3´ 
Ce6,15:G 5´-GUAAUCeGAAAGCAGCeAGGGtt-3´ 5´-CCCUGCUGCUUUCGAUUACtt-3´ 
Ce10,15:G 5´-GUAAUAGAACeGCAGCeAGGGtt-3´ 5´-CCCUGCUGCGUUCUAUUACtt-3´ 
     
 



























Figure 3.3. Caspase 2 inserts with Not I and Xho I restriction sites: (A) wild type (wt), 














(A)  5´-TCGAGcccgAACCCTTCTGCTTTCTATTACtagaGC-3´ 
       3´-CgggcTTGGGAAGACGAAAGATAATGatctCGCCGG-5´  
(C)  5´-TCGAGcccgAACCCTTCTGCGTTCTATTACtagaGC-3´ 
       3´-CgggcTTGGGAAGACGCAAGATAATGatctCGCCGG-5´ 
(B)  5´-TCGAGcccgAACCCTTCTGCTTTCGATTACtagaGC-3´ 
       3´-CgggcTTGGGAAGACGAAAGCTAATGatctCGCCGG-5´  
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mL cell culture flasks were used for growing cells. Water in the incubator pan was 
always autoclaved before use. The cells that were used in the experiments were between 
passage numbers 5 to 12. Cell confluence was kept between 50-70% for all RNAi assays.  
          The RNAi assay. During the day of the experiment, cells within the proper 
confluence level (~ 60%) were trypsinized and detached from the flask. Excess medium 
was added to inactivate trypsin. Cells were then centrifuged and re-suspended in fresh 
medium. Cells were counted manually by using a standard hemocytometer and diluted so 
that 6000 cells are present per 80 µL medium. Cells were kept in the incubator at 37 °C 
for about 45 min, while siRNA transfection complexes were being formed. siPORTTM 
NeoFXTM transfection agent was used as the siRNA delivery method in all cell culture 
studies. All siRNAs and plasmids were diluted in Opti-MEM® reduced serum medium, 
and siRNAs and plasmids were mixed together; similarly transfection agents were diluted 
in Opti-MEM® and transfection complexes were allowed to form. Then, siRNA-plasmid 
mixtures are added into diluted transfection agent solutions and mixed thoroughly by 
pipetting.  
          In all the experiments, 96-well plates were used and 20 µL siRNA-transfection 
complex was discharged into each well (Figure 3.5). The cell suspension was then taken 
out of the incubator and 80 µL of the cell suspension (containing 6000 cells) was added 
to each well. The plate was shaken several times and tilted several times to ensure 
homogenization of the two solutions. The plate was kept inside the incubator and within 
4 h, the transfection of the cells was complete. Cells were allowed to grow for 36 h and 
were assayed for caspase 2 mRNA insert silencing using the Dual-Glo™ Luciferase 
Assay System from Promega. Initially firefly luciferase emission was recorded and then  
















Reverse transfection of cells (6 x 103 per well) with plasmid and siRNA
Incubate for 42 hour
Quantify firefly luciferase intensity
Quantify Renilla luciferase intensity
Normalize expression of Renilla vs firefy luminescence
Calculate % expression of Caspase 2 insert mRNA
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by adding the Dual Glo Stop and Glo reagent, the firefly luciferase was terminated and 
Renilla luminescence was recorded. Ratios of Renilla to firefly luminescence of samples 
were used to compute percent expression of the caspase 2 mRNA.  
          The PKR binding assay. This experiment (Figure 3.6) was performed by Erik 
Fostvedt and Rachel Valenzuela in the laboratory of Professor Peter A. Beal, Department 
of Chemistry, University of California, Davis. U87 cells (approximately 8 x 106 in a 75 
cm2 flask) were treated 24 h before lysis with human interferon-α A (PBL Interferon 
Source) to a final concentration of 1 x 106 U L-1. The interferon-treated cells were washed 
twice with PBS and lysed by shaking with 3 mL solubilization buffer (50 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1% Triton X-100, supplemented with protease inhibitor cocktail 
(ProteoBlock, Fermentas) for 30 min on ice. The lysates were clarified by centrifugation 
at 14000 x g at 4 °C for 20 min and used directly in pull-down experiments.  
          Magnetic streptavidin beads (0.5 mg, 50 µL) (Dynabeads M-280, Invitrogen) were 
prepared for RNA manipulation according to the manufacturer’s protocol. Briefly, beads 
were suspended in 350 µL binding buffer (5 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 1 M 
NaCl) and coated with 100 pmol of siRNA (100 µL) by gently rocking for 30 min at 
room temperature. The siRNA-coated beads were washed twice with binding buffer (500 
µL) and once with solubilization buffer (500 µL) and incubated with 0.5 mL cell lysate 
for 20 min at room temperature.  Beads without siRNA were also incubated with cell 
lysate and served as a control.  After incubation, the beads were washed four times with 
500 µL wash buffer (20 mM HEPES, pH 7.9, 2.5 mM MgCl2, 100 mM KCl, 20% 
glycerol, 0.5 mL DTT, 0.2 mg/mL yeast RNA, 0.2 mg/mL salmon sperm DNA). Bound 
protein was eluted from the beads by heating in the loading buffer, separated on 6% SDS-  
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PAGE and transferred to a PVDF membrane for Western blotting.  Membranes were 
blocked with blotting-grade milk (Bio-Rad), incubated with PKR antibody (Santa Cruz 
Biotechnology, 1:1000 dilution), washed with TBS-Tween, and incubated with alkaline 
phosphatase-conjugated secondary antibody (Santa Cruz Biotechnology, 1:2000 
dilution). The proteins were detected using ECF substrate (GE Healthcare) on a Typhoon 
Trio Variable Mode Imager (GE Healthcare) and band intensities were quantified using 
ImageQuant software (Molecular Dynamics).  PKR binding affinity is reported as the 
average ratio of band intensities of modified siRNA to native siRNA for three 
independent experiments. 
 
Results and discussion 
          Thermal analysis of the 8-alkoxyA-containing siRNAs. Unmodified and 
modified (8-alkoxyA) guide strands were annealed to corresponding passenger strands 
(Tables 3.1 and 3.2) by heating to 90 °C and slowly cooling down to room temperature in  
2 h. The guide and passenger strands were designed in such a way that 8-alkoxyA faces 
G or U in the corresponding passenger strands. The unmodified A:U duplex was used as 
a reference, based upon which the thermal stabilities of the singly- and doubly-modified 
duplexes (both 8-ROA:U and 8-ROA:G) were analyzed. In the case of the 8-ROA:U base 
pair, the 8-ROA nucleoside can adopt the canonical anti orientation around the glycosidic 
bond. For the 8-ROA:G pair, 8-ROAsyn:Ganti  and 8-ROAanti:Ganti combinations were 
considered, while other A:G combinations were deemed too distorting to exist in an A-
form duplex RNA. However, the 8-ROAanti:Ganti pair will widen the helix diameter 
considerably and introduce strain into the duplex; additionally, the presence of a 
significantly large alkoxy group at position 8 of the purine ring favors the 8-ROAsyn:Ganti 
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combination. Thus, the existence of 8-ROAanti:Ganti cannot be ruled out, but 8-
ROAsyn:Ganti  is more likely to occur in A-form duplex RNA.  
          All singly and doubly modified duplexes displayed lower melting temperatures 
(Tm) compared to the unmodified duplex (Figures 3.7 and 3.8).  Therefore, the alkoxy 
group appears to introduce instability in the RNA duplexes. In all duplexes, the 8-ROA:U 
base pair was found to be more stable than the 8-ROA:G base combination implying that 
the Watson-Crick hydrogen-bonding is still preferred in these modified adenosines, 
provided that 8-ROA faces U as the complementary base. Although 8-ROA:G also has a 
greater potential to expose its Hoogsteen face to anti G, steric clash between the alkoxy 
group of 8-ROA and the exocyclic amine of G in the minor groove might undermine the 
strength of hydrogen bonding resulting in lower Tm values for 8-ROA:G.  
          Melting temperatures also varied depending on the position of the 8-alkoxyA base 
in the guide strand.  It is not clear why the 5´-end of the guide strand can tolerate 
modifications of variable size more effectively than the other end.  The 5´-end of the 
guide strand is thermodynamically less stable and hence more prone to unzipping; 
introducing a destabilizing nucleoside in this region, as opposed to the other end, should 
further decrease the thermal stability of the duplex.  Again at positions 10 and 15, the 8-
alkoxyAs are between two purines, so a greater stacking interaction is expected.  These 
siRNAs would be expected to have higher melting temperatures compared to siRNAs 
bearing these modifications at positions 4 and 6.  In practice however, the reverse trend is 
observed.  In all cases, higher duplex stability was obtained when the modifications are 
closer to the 5´-end of the guide strand. Modifications in the middle position (10) or 
towards the 3´-end (15) of the guide strand always exhibited reduced thermal stability. 










Figure 3.7. Thermal analysis of the siRNA duplexes with single 8-alkoxyA 
modifications at four different positions, 4, 6, 10 and 15, in the guide strand. 
Modifications were placed opposite to U or G in the corresponding passenger strands. 
The sequences are shown in the tables 3.1 and 3.2; here M represents 8-PgOA, 8-PeOA 
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SiRNA modifications and positions 
         5'-CCCUNCUGCNUUCNANUACdTdT-3' 
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Figure 3.8. Thermal analysis of the siRNA duplexes with double 8-alkoxyA 
modifications at three different positions, 6, 10 and 15, in the guide strand. Modifications 
were placed opposite to U or G in the corresponding passenger strands. The sequences 
are shown in the tables 3.1 and 3.2; here M is 8-PgOA, 8-PeOA or 8-CeOA, and N is 
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SiRNA modifications and positions 
        5'-CCCUNCUGCNUUCNANUACdTdT-3' 
3'-dTdTGGGAMGACGMAAGMUMAUG-5'             
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          For single modifications, lowering of the Tm was moderate for modifications at 
positions 4 and 6 opposite U (e.g., Pg4:U, Pg6:U, Ce4:U); however single modifications 
at positions 10 and 15 exhibited significantly lower Tm irrespective of their placement 
opposite to G or U. As expected, reduction in duplex stability was more pronounced (7-
14 °C) for doubly modified duplexes. Interestingly, except for position 15, the size of the 
alkoxy groups did not have much influence on the thermal stability of siRNA duplexes.  
           A similar trend was noticed in 8-ClA-containing RNA duplexes which also have 
lower melting temperatures compared to the unmodified duplexes (56). Therefore, 
thermal destabilization cannot be primarily linked to the substituent size and shape effect, 
but also to substituent electronegativity values.  Because both Cl and O have higher 
electronegativities compared to H, a strong electron withdrawing inductive effect may 
operate to reduce electron density in the purine rings significantly, and hence this can 
reduce the stability of hydrogen bonds formed by 8-ClA:U or 8-ROA:U in the Watson-
Crick base pairing and affect base stacking as well.  
          Lowering of the Tm in the 8ROA:U base pair compared with the A:U base pair can 
also be explained in terms of a relatively pronounced syn preference of 8-substituted 
purines over the anti conformation, both in the context of DNA (57, 58) and RNA (56, 
59-61) nucleosides and duplex oligonucleotides. X-ray crystallographic (59) and CD 
studies (60) of 8BrA and the corresponding 5´-monophosphate have shown that these 
molecules predominantly exist in the syn conformation around the glycosidic bond due to 
the presence of a sterically demanding Br atom at position 8 in the purine ring. Although 
the van der Waals radius of Cl (1.80 Å) is significantly smaller than Br (1.95 Å), 
theoretical calculations predicted preferentially the syn conformation even for 8-ClA 
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nucleosides (61). Importantly, a relative lowering of melting temperature of A:U vs. A:G 
combination was noticeably greater than the 8-ROA:U vs. 8ROA:G combinations. 
Interestingly, this difference shrank even more for the 8-PeOA and 8-CeOA containing 
duplexes, implying that with increasing the steric bulk of the alkoxy group, the syn 
preference of the 8-alkoxyadenosines increased.  All these observations fit well with the 
preferential syn conformation of the 8-substituted-adenosines, such as 8-ClA and 8-ROA, 
in the duplex RNA context.  
          Caspase 2 mRNA knockdown studies with the modified siRNAs. To analyze 
caspase 2 expression levels quickly and reliably, a plasmid-based dual luciferase assay 
system was employed.  A fragment of the caspase 2 mRNA sequence was inserted into 
the psiCHECK2 vector, and the resulting reporter plasmid was used to evaluate caspase 2 
mRNA knockdown.   
          Singly substituted siRNAs, alkoxylated at several positions of the guide strand, 
exhibited almost equivalent or slightly lower silencing effects compared to the 
unmodified caspase 2 siRNA (Figure 3.9). Among singly modified siRNAs, 8-PgOA 
exhibited the highest mRNA knockdown efficiency. Surprisingly, 8-CeOA modifications, 
even though the largest among three modifications, showed almost equal knockdown 
efficiency to 8-PgOA, whereas, 8-PeOA containing siRNAs were found to have the 
lowest efficacy. Thus, the mRNA knockdown ability of the modified caspase 2 siRNAs 
does not directly correlate with the substituent size.  
          Interestingly, singly modified siRNAs with intermediate thermal stability 
(modifications at positions 6 and 10) exhibited higher RNAi efficacy than those having 
the highest (modification at position 4) or the lowest (modification at position 15)  








Figure 3.9. RNAi studies with the singly modified siRNAs. % Expression of Renilla 
luciferase relative to firefly luciferase when treated with siRNAs bearing single 8-
alkoxyA modification at position 4, 6, 10 or 15 in the guide strand. 8-AlkoxyA (8-PgOA, 
8-PeOA or 8-CeOA) modifications were placed opposite to G (in the passenger strand) 
during delivery and U (in the mRNA) in the RISC. The siRNA sequences are depicted in 
Table 3.2. Experiments were conducted at three different concentrations: 50 nM, 0.5 nM 
























SiRNA modifications and positions  
No siRNA 50 nM 0.5 nM 0.01 nM 
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stability (Figure 3.9). This observation supports the basic rules of siRNA design and 
efficacy, which emphasizes that, for optimal efficacy, the thermal stability of the siRNA 
duplexes be intermediate, neither very high, nor very low (62, 63). If the stability is too 
high then RISC will be unable to unzip the siRNA duplexes, and hence mRNA 
knockdown efficiency will be lowered. On the other hand, if the duplex stability is low 
then the effective concentration of double-stranded siRNAs will be lowered and RNAi 
efficacy will be drastically reduced. Because the differences in Tm among the four 
sequence contexts is not very high, their influence on the RNAi efficacy engenders 
curiosity.  
          In all cases, modifications at position 10 of the guide strand exhibited the highest 
gene-silencing efficacy, followed by position 6.  Modifications at position 15 seemed to 
reduce the potency of siRNAs, with the exception of the propargyloxy modification, 
which was found to be equally active when compared to other positions in the series. So, 
position 15 was found to tolerate smaller groups better as opposed to larger groups such 
as phenylethoxy and cyclohexylethoxy groups. This trend is somewhat unexpected, since 
it is already known that substitutions towards the 3´-end of the guide strand typically can 
tolerate chemical modifications and even mismatches rather well (11, 38). Contrarily, the 
seed region and the cleavage site are more sensitive to chemical modifications and 
mismatches, in general.  Sometimes, a single mismatch (62) at the center or chemical 
modifications distorting the A-form duplex structure (6) abolishes the efficacy of the 
corresponding siRNA. In this case, modifications in two important positions of the seed 
region with large substituents are quite well tolerated.  More surprisingly, a large 
modification adjacent the cleavage site (position10) actually rendered the siRNA more 
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effective towards knocking down caspase 2 mRNA.  This trend was observed for all 
modifications; however with larger modifications such as 8CeOA and 8PeOA, this trend 
was observed without any ambiguity. The presence of a hydrophobic pocket at the 
corresponding position in Argonaute2 in the RISC might be a plausible explanation for 
this observation (64).  
          Multiple 8-ROA substitutions at the guide strands showed significantly reduced 
silencing efficacy compared to their corresponding positive control siRNAs or single 
modifications (Figure 3.10). This trend holds irrespective of the substituent size, shape 
and position. These siRNAs only exhibit significant mRNA knock down at 50 nM 
concentrations.  
          Modified purines at positions 6 and 10 in the guide strand opposite to G or U (in 
the passenger strand) did not substantially change the knock down efficiency (Figure 
3.11).  In most of the cases, delivering the modified purine opposite to G brought about 
almost equal or slightly higher mRNA knockdown than delivering it opposite to U.  Only 
with Ce6, a reverse trend was observed, though it was only by a small margin. These data 
suggest that both 8-ROA:G and 8-ROA:U can be loaded into the RISC with equal 
efficiency. 
          Importance of Switching the Steric Blockade from the Minor to the Major 
Groove in the RISC. To explore the importance of ‘base switching’ in the context of 
RISC-mediated cleavage of caspase 2 mRNA, two mutant plasmids, P6 and P10 were 
synthesized using appropriate inserts by mutating specific positions of the wild-type 
caspase 2 insert. Two important sites in the guide strand of the caspase 2 siRNA, 
positions 6 (in the seed region) and 10 (adjacent the cleavage site) were chosen for the 








Figure 3.10. RNAi studies with the doubly modified siRNAs. % Expression of the 
Renilla luciferase relative to the firefly luciferase when treated with siRNAs bearing 
double 8-alkoxyA (8-PgOA, 8-PeOA or 8-CeOA) modifications in three different 
combinations in the guide strand: (6, 10), (6, 15) and (10, 15). 8-AlkoxyA modifications 
were placed opposite to G in the passenger strand during delivery and U (in mRNA) in 
the RISC. The siRNA sequences are depicted in Table 3.2. Experiments were conducted 
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Figure 3.11. % Expression of the Renilla luciferase relative to the firefly luciferase when 
treated with siRNAs bearing 8-alkoxyA (8-PgOA, 8-PeOA or 8-CeOA) modifications at 




























G U G U G U G U G U G U 








SiRNA modifications and positions 
No siRNA 50 nM 0.5 nM 
	  	  	  
111	  
construction of mutant plasmids, P6 and P10.  In such cases, the 8-alkoxyAs face G as 
the complementary base both during the siRNA delivery and during interaction of the 
guide strand with the mRNA in the RISC. Therefore, alkoxy steric blockades will be 
presented in the minor groove both in the guide-passenger and guide-mRNA constructs.   
          As expected, the mRNA knockdown efficiency was drastically reduced for all three 
(8-PgOA 8-PeOA and 8-CeOA) modifications; 8-PgOA being the smallest in size is 
relatively more efficacious (Figures 3.12 and 3.13). In the case of A:G mismatched guide 
SiRNA:mRNA constructs, a similar decrease in mRNA knockdown efficiency was 
noticed with respect to both mutant plasmids, P6 and P10.   
          These results indicate that for the guide:mRNA duplex, both local widening (65) 
(due to the A:G pair) or minor groove crowding (due to the 8ROA:G pair) can lead to 
drastic reduction of the mRNA knockdown efficacy. Probably these distortions in the 
guide:mRNA duplex do not allow the necessary protein side chain interactions in the 
guide:mRNA:RISC ternary complex.  
          The PKR binding studies. To assess the effect of these modifications on siRNA 
binding to an off-pathway dsRNA-binding protein, we used a PKR binding assay 
involving immobilized biotinylated siRNA (11). These experiments were conducted by 
Erik Fostvedt and Rachel Valenzuela in the laboratory of Prof. Peter A. Beal, Department 
of Chemistry, University of California, Davis. 5´-Biotinylated passenger strands with 
either U or G opposite to the modified purines were annealed to Pg6, Ce6, Pe6, Pg10, 
Ce10, Pe10 and unmodified guide strands. The biotinylated duplexes were attached to 
magnetic streptavidin beads and used in affinity purification for PKR. The degree of PKR 
binding for each duplex was then analyzed by western blot.  












Figure 3.12. RNAi studies on the P6 mutant plasmid (caspase 2 insert containing plasmid 
mutated at position 6 corresponding to the guide siRNA). % Expression of the Renilla 
luciferase relative to the firefly luciferase, when treated with siRNAs bearing 
modifications at position 6 in the guide strand, and targeted U (from A6:U plasmid, 
depicted by solid bars) vs. G (from C6:G plasmid, depicted by hashed bars) in the 
caspase 2 insert and mutant caspase 2 insert mRNA respectively. Sequences are given in 
Tables 3.1 and 3.2. Experiments were conducted at two different concentrations: 50 nM 
and 0.5 nM. A:U, Pg6:U, Ce6:U and Pe6:U represents targeting of U in the caspase 2 
insert mRNA (from A6:U plasmid) and C:G, A6:G, Pg6:G, Ce6:G and Pe6:G represents 
targeting of G in the mutant mRNA where a U was mutated to G (from C6:G plasmid). 
Nomenclature of the plasmid comes from corresponding modification position in the 
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Figure 3.13. RNAi studies on the P10 mutant plasmid (caspagse 2 insert containing 
plasmid mutated at position 10 corresponding to the guide siRNA). % Expression of the 
Renilla luciferase relative to the firefly luciferase, when treated with siRNAs bearing 
modifications at position 10 in the guide strand, and targeted U (from A10:U plasmid, 
depicted by solid bars) vs. G (from C10:G plasmid, depicted by hashed bars) in the 
caspase 2 insert and mutant caspase 2 insert mRNA, respectively. Sequences are given in 
Tables 3.1 and 3.2. Experiments were conducted at two different concentrations:  50 nM 
and 0.5 nM. A:U, Pg10:U, Ce10:U and Pe10:U represent targeting of U in the caspase 2 
insert mRNA (from A6:U plasmid) and C:G, A10:G, Pg10:G, Ce10:G and Pe10:G 
represent targeting of G in the mutant mRNA where a U was mutated to G (from C10:G 
plasmid). Nomenclature of the plasmid comes from corresponding modification position 
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          Our results show that different types of modifications, when placed in the guide 
strand opposite to G or U in the passenger strand, are significantly less prone to bind to 
PKR compared to the unmodified sequences (Figures 3.14 and 3.15). Unmodified 
siRNAs with A:G mismatches at positions 6 and 10 are almost as susceptible to bind 
PKRs as the unmodified one. So, prevention of protein binding is not a result of mere 
bulges due to A:G mismatches, but rather an outcome of the placement of different steric 
blockades in the minor and major groove by means of placing 8-alkoxyA opposite to U 
or G.  
          With propargyloxy modifications being the smallest in size of those studied here, 
Pg6:G, Pg10:U and Pg10:G P were the least effective in preventing PKR binding with the 
exception of Pg6:U; whereas all cyclohexylethoxy and phenylethoxy modifications 
reduced the PKR binding significantly. It seems that PKR is slightly more prone to bind 
to modified siRNAs where U in the passenger strand was placed opposite to the 
modification in the guide strand than to siRNAs where modifications are opposite to G. 
In some cases (for example, Pg10:U vs. Pg10:G, Pe10:U vs. Pe10:G) this discrimination 
is more pronounced, and in some cases (Pg6:U vs. Pg6:G, Pe6:U vs. Pe6:G) less.  These 
data suggest that this type of steric occlusion of the minor groove is moderately or 
marginally advantageous over the major groove occlusion.  Surprisingly, when 8-CeO 
modifications were placed in position 6 and 10 opposite to U or G, no distinction was 
observed between the binding affinities towards PKR.  Both Ce6:G and Ce6:U were 
equally effective in preventing PKR binding. A similar trend with lesser efficacy was 
observed with Ce10:G and Ce10:U.  
 








Figure 3.14. PKR binding to the modified siRNAs containing 8-alkoxyadenosine 
‘switches’. (A) Biotinylated siRNAs were bound to magnetic streptavidin beads and 
treated with lysates from U87 cells treated with IFN-α. The amount of PKR retained was 
determined by western blotting. Cyclohexylethoxy (Ce), phenylethoxy (Pe), and 
propargyloxy (Pg) modifications were tested at positions 6 and 10 opposite either G 
(Blue) or U (Red).  Strands with A:G mismatches were also tested at positions 6 and 10 
as controls (Green).  (B). A representative western blotting consisting of 1. Unmodified 
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Figure 3.15. Typical western blot results for each of the duplexes tested for off-pathway 
protein-binding. Each modified strand (column 2) presented here is in comparison to the 
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          There are other reports of prevention of PKR binding by manipulating minor 
groove modifications (10, 11, 39); however, there is no report, so far, of any major 
groove modification that is equally efficient in attenuating siRNA-PKR interaction when 
placed in the same position of an siRNA.  8-PeOA and 8-CeOA modified siRNAs are the 
first examples to exhibit such a characteristic.  From the thermal analysis data and RNAi 
studies with mutant plasmids, it is clear that 8-ROA:U and 8:ROA:G combinations are 
distinct, their differences likely related to different glycosidic bond conformations and 
placement of the steric blockades.  
          Kannan et al. reported N2-alkylated 2´-deoxy-7,8-dihydro-8-oxoguanosine-based 
switches are capable of preventing PKR binding only when the steric blockade is placed 
in the minor groove as opposed to the major groove (39). In that study N2 -propyl and N2-
benzyl modified 8-oxoguanines were used. The phenylethoxy and cyclohexylethoxy 
groups used here are not only larger, but also significantly longer than the propyl and 
benzyl groups used in the previous studies. Additionally, substitution of the position 8 of 
purines with bulky alkoxy groups might significantly affect the overall structure of the 
major and the minor groove, which might also contribute towards prevention of the PKR 
binding. Hence, irrespective of their position in either groove, these larger and longer 
groups repel PKRs to a much greater extent.  
          Another probable rationale for the high activity of 8ROA:U might be the 
modification site (position 8) of adenosine itself. PKR is known to bind dsRNA by 
interacting with two segments of the minor groove and the intervening major groove (66). 
In the major groove, lysine side chains of PKR interact with the negatively charged 
phosphate backbone of dsRNA. Hence, appropriate major groove modifications of the 
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siRNA can potentially prevent this electrostatic interaction and block PKR binding.  In 
the case of 8ROAanti:U-containing siRNAs, the alkoxy group is suitably positioned to 




          A general solution to sequence-independent off-pathway protein binding of 
siRNAs, while maintaining mRNA knock down efficacy, was investigated here. The 
study also explored the scope of guide strand modifications by utilizing 8-
alkoxyadenosines of variable alkyl group size.  This is an unusual example in which a 
purine ribonucleoside is proposed to exist in both syn and anti conformations around the 
glycosidic bond depending on the base-pairing partner. 8-Alkoxyadenosine modifications 
were tolerated both in singly and doubly modified duplexes irrespective of G or U as the 
pairing partner, although lowering of the Tm is very pronounced in cases of multiple 
modifications.  Singly modified siRNAs were almost the same or slightly less effective in 
RNAi, whereas multiply modified siRNAs exhibited much lower caspase 2 insert mRNA 
knock down activity.  Singly modified siRNAs were capable of inhibiting PKR-siRNA 
interactions compared to the unmodified siRNA. The necessity of ‘base switching’ in the 
RISC was demonstrated by using two caspase 2 inserts, individually mutated at positions 
6 and 10.  To confirm the syn vs. anti conformational preference of 8-substituted 
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CONCLUSION AND FUTURE DIRECTIONS 
 
 
          Numerous chemical modifications have been implemented to make siRNA 
therapeutically more potent and selective. In addition to the phosphate backbone and the 
ribose modifications, several successful base modifications have also been reported. 
Modifying passenger strand bases is more difficult compared to other modifications, and 
it is extremely challenging to modify guide strand bases. However, base modifications of 
the siRNA can help explore the effect of H-bonding and sterics in the context of RNAi 
machinery. In this study, 8-alkoxyadenosines were introduced into the guide strands and 
their effects on the RNAi efficacy and the off-pathway protein binding were explored. 
          8-Substituted purines are known to exist in an equilibrium mixture of syn/anti 
conformations. Hence, here 8-alkoxyadenosines were used as a conformational ‘switch’ 
to mediate RNAi and alleviate off-pathway protein binding efficiently. 8-AlkoxyA 
phosphoramidites were synthesized and incorporated into the guide strand of a caspase 2 
siRNA. Alkoxy groups were chosen based on their sizes and shapes. 
          All the singly and doubly modified guide strands formed stable duplexes with 
appropriate passenger strands, although the thermal stability of the siRNAs gradually 
decreased with each substitution. The thermal stability of the duplex oligoribonucleotides 
did not depend too much on the size of the alkoxy group. Electron withdrawing inductive 
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effect of O is thought to weaken the hydrogen bonding between the modified nucleoside 
and the complementary base, resulting in lower Tm values for the modified siRNAs. 
          The singly modified siRNAs have RNAi efficacy similar to the unmodified 
positive control; but double substitutions of 8-alkoxyA in the guide strand significantly 
lowers the RNAi efficacy. All 8-alkoxyA modifications were tolerated in the seed region 
and at the cleavage site of the siRNA. The phenylethoxy modification was found to be 
the least effective among all modifications.   
          Modifications at positions 6 and 10, when placed opposite to U or G, could prevent 
the off-pathway interaction of siRNA with the PKR. Placement of the steric blockade in 
the minor groove (8-alkoxyA:G) was effective in preventing PKR binding; surprisingly 
steric blockades, when placed in the major groove (8-alkoxyA:U) were also effective, 
although to a lower extent than the earlier mode of placement, in knocking down the 
siRNA-PKR interaction.  
          From the Tm analysis, RNAi studies and PKR binding experiments, it can be 
inferred that 8-alkoxyAs have the potential to exist in both syn and anti conformation 
depending on the base-pairing partner. However, ‘switching’ of the 8-alkoxyadenosine 
nucleosides can be explored comprehensively and unambiguously only through direct 
structural analysis of the duplex RNAs containing these lesions. Both X-ray 
crystallography and NMR spectroscopy can be used to explore the base switching, but x-
ray crystallographic analysis of the duplex RNA is extremely difficult since crystalizing 




          Structural analysis of double-stranded RNA and DNA employing 1D and 2D NMR 
spectroscopic methods is a routine procedure these days; however most of the previous 
studies involved natural bases. In exploring hydrogen bonding between bases, 1D 
immino region spectrum and 2D nuclear Overhauser effect spectroscopy (NOESY) are 
valuable techniques and will be employed here.  
          Initially, a 14-mer self-complementary RNA duplex (Figure 4.1) of reasonable 
thermal stability was taken as the reference strand. 8-Propargyloxyadenosine was chosen 
as a representative modification to explore the switching probability of the 8-
alkoxyadenosines. Initially, we wanted to explore the switching mechanism with 
nucleosides such as 8-BrdA or 8-PrNHdA, which are known to exist in both syn and anti 
conformation depending on the base-pairing partner. Also, substituting a single 
ribonucleotide with a deoxyribonucleotide does not affect the helical geometry of the 
double-stranded RNA – it is still an A form helix. Locating different conformers of a 
deoxyribonucleotide will be easier in the 2D NMR of a duplex RNA and, thus, can serve 
as the starting point in this structure elucidation project.  8-BrdA was found to be acid-
labile and therefore we designed strands containing 8-PrNHdA; later 8-PrgOA would be 
used in place of 8-PrNHdA. 
          To summarize, an unusual base modification, 8-alkoxyA, in the guide strand was 
found to be functional in mediating RNA interference and preventing off-pathway PKR 
binding with the siRNA in cultured mammalian cells.  The next step would be to evaluate 
efficacy of these modifications in animal models. These of modifications also hold 









Figure 4.1. Self-complementary 14-mer RNA duplexes depicting (A) 8-PrNHdA:U and 




































nostimulation.  Similar modifications with added properties, such as fluorescence, might 
help explore details of the RNAi mechanism. 
          Structural analysis of 8-PrNHdA containing self-complementary duplex RNAs is 
currently under investigation. Each duplex contains two 8-PrNHdA nucleotides in two 
strands and U or I opposite to these modified bases. Our hypothesis is that 8-PrNHdA 
will adopt the syn conformation when placed opposite I, whereas it will adopt an anti 
conformation when it faces U in the complementary strand. The structural features of 
different conformations will be explored through 1D imino region 1H NMR and 2D 
NOESY. Similar experiments will be conducted with 8-PrgOA in place of 8-PrNHdA to 
elucidate the ‘base-switching’ hypothesis related to 8-alkoxyadenosines. 
 
       
